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Summary 
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent childhood-onset 
neurodevelopmental disorder that involves a substantial risk of persisting into 
adolescence and adulthood. A number of genome-wide screening studies in ADHD 
have been conducted in recent years, giving rise to the discovery of several variants 
at distinct chromosomal loci, thus emphasising the genetically complex and polygenic 
nature of this disorder. Accordingly, promising novel candidate genes have emerged, 
such as the gene encoding the glucose transporter isoform 3 (SLC2A3) and the gene 
encoding the latrophilin isoform 3 (LPHN3).  
In this thesis, both genes were investigated in form of two separated projects. The 
first focused on SLC2A3 polymorphisms associated with ADHD and their potential 
physiological impact. For this purpose, gene expression analyses in peripheral cell 
models were performed as well as functional EEG measurements in humans. The 
second project concerned the murine gene Lphn3 including the goal of developing a 
mouse line containing a genetically modified Lphn3 with conditional knockout 
potential. In this respect, a specific DNA vector was applied to target the Lphn3 gene 
locus in murine embryonic stem (ES) cells as a prerequisite for the generation of 
appropriate chimeric mice. 
The results of the first project showed that SLC2A3 duplication carriers displayed 
increased SLC2A3 mRNA expression in peripheral blood cells and significantly 
altered event-related potentials (ERPs) during tests of cognitive response control and 
working memory, possibly involving changes in prefrontal brain activity and memory 
processing. Interestingly, ADHD patients with the rs12842 T-allele, located within and 
tagging the SLC2A3 gene, also exhibited remarkable effects during these EEG 
measurements. However, such effects reflected a reversed pattern to the 
aforementioned SLC2A3 duplication carriers with ADHD, thus indicative of an 
opposed molecular mechanism. Besides, it emerged that the impact of the 
aforementioned SLC2A3 variants on different EEG parameters was generally much 
more pronounced in the group of ADHD patients than the healthy control group, 
implying a considerable interaction effect. Concerning the second project, preliminary 
results were gathered including the successful targeting of Lphn3 in murine ES cells 
as well as the production of highly chimeric, phenotypically unremarkable and
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mostly fertile mouse chimeras. While germline transmission of the modified Lphn3 
allele has not yet occurred, there are still several newborn chimeric mice that will be 
tested in the near future.  
In conclusion, the findings suggest that SLC2A3 variants associated with ADHD are 
accompanied by transcriptional and functional changes in humans. Future research 
will help to elucidate the molecular network and neurobiological basis involved in 
these effects and apparently contributing to the complex clinical picture of ADHD. 
Moreover, given the increasing number of publications concerning latrophilins in 
recent years and the multitude of research opportunities provided by a conditional 
knockout of Lphn3 in mice, the establishment of a respective mouse line, which 
currently is in progress, constitutes a promising approach for the investigation of this 
gene and its role in ADHD. 
 
 
Zusammenfassung 
Das Aufmerksamkeitsdefizit/Hyperaktivitätssyndrom (ADHS) ist eine hoch prävalente 
und bereits in der Kindheit beginnende Neuroentwicklungsstörung, die eine 
erhebliche Persistenz ins Jugend- und Erwachsenenalter aufweist. In den 
vergangenen Jahren wurde eine Vielzahl von genomweiten Studien zu ADHS 
durchgeführt, welche zur Identifizierung zahlreicher genetischer Varianten an 
unterschiedlichen chromosomalen Loci geführt und somit die genetisch komplexe 
polygene Natur dieser Störung zur Geltung gebracht haben. Auf diese Weise traten 
auch neue Kandidatengene zutage, wie zum Beispiel das Gen für die 
Glukosetransporter-Isoform-3 (SLC2A3) und das Gen, welches Latrophilin-3 kodiert 
(LPHN3).  
Innerhalb dieser Thesis wurden beide Gene in Form von zwei voneinander 
getrennten Projekten untersucht. Das erste Projekt beschäftigte sich mit humanen 
ADHS-assoziierten SLC2A3-Polymorphismen und ihrer potentiellen physiologischen 
Bedeutung. Für diesen Zweck wurden Genexpressionsanalysen in peripheren 
Zellmodellen sowie funktionelle EEG-Messungen im Menschen durchgeführt. Im 
zweiten Projekt ging es um das murine Gen Lphn3 mit dem Ziel, eine Mauslinie zu 
entwickeln, die ein genetisch verändertes Lphn3 mit konditionalem Knockout-
Potenzial aufweist. In diesem Zusammenhang wurde ein spezifischer DNA-Vektor 
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verwendet, der auf den Lphn3-Genlocus in murinen embryonalen Stammzellen (ES-
Zellen) abzielte, was eine Voraussetzung für die Erzeugung von geeigneten 
chimären Mäusen darstellt.  
Die Ergebnisse des ersten Projektes legten nahe, dass SLC2A3-Duplikationsträger 
erhöhte SLC2A3-mRNA-Expression in peripheren Blutzellen aufweisen sowie 
signifikant veränderte ereigniskorrelierte Potentiale während eines Tests kognitiver 
Reaktionskontrolle sowie eines Arbeitsgedächtnis-Tests, was möglicherweise von 
veränderter präfrontaler Hirnaktiviät bzw. Gedächtnis-Prozessierung begleitet wird. 
Interessanterweise zeigten ADHS-Patienten mit T-Allel des im SLC2A3-Gen 
liegenden SNPs rs12842 ebenfalls deutliche Effekte während dieser EEG-
Messungen, allerdings in entgegengesetzter Form zu den zuvor genannten SLC2A3-
Duplikationsträgern mit ADHS, was auf einen gegensätzlichen molekularen 
Mechanismus hindeutet. Zudem stellte sich heraus, dass der Einfluss der zuvor 
genannten SLC2A3-Varianten auf verschiedene EEG-Parameter innerhalb der 
ADHS-Gruppe generell deutlich stärker ausgeprägt war als in der gesunden 
Kontrollgruppe, also einen beachtlichen Interaktionseffekt impliziert. Bezüglich des 
zweiten Projektes konnten bisher Zwischenergebnisse erzielt werden: das 
erfolgreiche Targeting des Lphn3-Gens in murinen ES-Zellen sowie die Produktion 
hochchimärer, phänotypisch unauffälliger und größtenteils fertiler Maus-Chimären. 
Obgleich die Keimbahntransmission des modifizierten Lphn3-Allels bislang noch 
nicht eingetreten ist, gibt es noch eine Reihe an neugeborenen chimären Mäusen, 
die in nächster Zeit erst noch getestet werden müssen.   
Zusammenfassend deuten die Ergebnisse darauf hin, dass Variationen des SLC2A3-
Gens, die mit ADHS assoziiert sind, mit transkriptionellen und funktionellen 
Veränderungen im Menschen einhergehen. Zukünftige Forschungsarbeiten werden 
dabei helfen, die molekularen Netzwerke und neurobiologischen Grundlagen zu 
verdeutlichen, die an diesen Effekten beteiligt sind und offenbar zu dem komplexen 
klinischen Bild von ADHS beitragen. Angesichts der steigenden Zahl an 
Publikationen über Latrophiline in den letzten Jahren und der unzähligen 
Forschungsmöglichkeiten, die ein konditionaler Knockout von Lphn3 in Mäusen 
bietet, stellt die derzeit laufende Etablierung einer entsprechenden Mauslinie einen 
vielversprechenden Ansatz dar, dieses Gen und seine Rolle für ADHS zu 
untersuchen. 
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1 Introduction 
1.1 Attention-deficit/hyperactivity disorder (ADHD) 
1.1.1 Characteristics and clinical diagnosis 
Attention-deficit/hyperactivity disorder (ADHD) is a complex and clinically hetero-
geneous neurobehavioural disorder which is characterised by developmentally 
inappropriate deficits in attention, increased activity and impulsivity as well as 
emotional dysregulation. With a worldwide prevalence estimated at around 5-10% in 
children and 2-4% in adults (Fayyad et al., 2007) ADHD constitutes one of the most 
common neuropsychiatric disorders.  
 
Published in 1994 by the American Psychiatric Association, the fourth edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) describes distinct 
diagnostic criteria for ADHD, essentially listing two main dimensions as inattention 
and hyperactivity/impulsivity. For diagnosis of ADHD, a sufficient number of 
symptoms of at least one dimension must have appeared within the past six months 
and to an extent that is maladaptive and not appropriate to the child’s developmental 
stage. If at least six of nine symptomatic criteria of both dimensions are met, the 
combined subtype of ADHD is diagnosed. By contrast, if only one dimension applies, 
it will be referred to as a predominantly inattentive or hyperactive subtype, 
respectively. In any case, some maladaptive symptoms have to emerge before the 
age of seven and in more than one area of the child’s life (e.g. at home and in 
school).  
 
Despite ADHD being rather known as a childhood disorder, it has been found to 
exhibit a high degree of persistence into adolescence and adulthood, amounting to 
approximately 40-60% (Faraone et al., 2006). Whereas symptoms of hyperactivity 
tend to decline with increased age or change into the feeling of inner restlessness, 
attention deficits frequently remain and are for example manifest in daydreaming or 
poor concentration. ADHD often involves severe impairments affecting the academic, 
economic and social life of patients. Among others, ADHD status tends to be a 
predictor for antisocial behaviour, substance abuse and unemployment (Barkley et 
al., 2004; Halmøy et al., 2009). 
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1.1.2 Comorbidities 
ADHD patients are known to show significantly higher prevalence of comorbid 
psychiatric disorders throughout their lifespan. During childhood, ADHD is often 
accompanied by oppositional defiant disorder, followed by anxiety and learning 
disorders, mood disorders as well as conduct disorder, whereas the most frequent 
comorbidities in ADHD adults are anxiety and mood disorders as well as antisocial 
and substance use disorders (Biederman, 2005).  
 
1.1.3 Therapy 
ADHD therapy involves a range of pharmacological and non-pharmacological 
interventions that mainly aim to reduce symptoms and help patients to cope with their 
situation. Pharmacotherapy is primarily based on psychostimulants such as 
methylphenidate or d-amphetamine. However, non-stimulants including clonidine or 
atomoxetine have also been shown to treat ADHD with some efficacy (for a review, 
see Antshel et al., 2011). Most ADHD drugs target the central monoaminergic 
systems, and particularly the neurotransmitters dopamine and norepinephrine. For 
example, MPH is referred to as a dopamine and norepinephrine transporter blocker 
(Hannestad et al., 2010) while clonidine is considered an α2-adrenoceptor agonist 
(Fu et al., 2001). Such pharmacological interventions are generally thought to 
increase the synaptic availability of particular monoaminergic neurotransmitters.  
 
On the other hand, several non-pharmacological treatments are available for ADHD, 
such as cognitive behavioural therapy, school interventions or parent training in 
behaviour management. In many cases an individualised multimodal therapy is 
recommended, namely a combination of both pharmacological and non-
pharmacological interventions, especially if treatment is not restricted to the 
amelioration of mere symptoms but also includes practices in social or self-
structuring skills which are often poorly developed in ADHD patients.  
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1.1.4 Heritability and molecular genetics 
It has been known for many decades that ADHD symptoms tend to aggregate in 
families both within and across generations. Numerous family, twin and adoption 
studies emphasise the comparably strong genetic component of ADHD, with a 
heritability ranging at approximately 0.76 (Faraone et al., 2005). However, similar to 
many other neuropsychiatric disorders, the genetic background of ADHD is 
considered complex and heterogeneous, implicating a multitude of potential risk 
genes with a likely modest to very small individual contribution to the pathogenesis.  
 
Concerning the molecular genetics of ADHD, important progress has been made by 
means of genome-wide linkage scans that help to find chromosomal regions shared 
unusually often within ADHD-affected families. Typically, this method relies on a vast 
panel of genetic markers spread out across the genome and whose segregation 
pattern is compared among family members. In a meta-analysis estimating the 
results of seven genome-wide linkage studies of ADHD, Zhou and colleagues found 
10 different genomic regions with at least nominally significant linkage signals, albeit 
with only 16q23.1 reaching genome-wide significance (Zhou et al., 2008). Given that 
linkage studies largely serve to identify loci with moderate or large effects, other 
strategies, and particularly via the genome-wide association study (GWAS) 
methodology, have to be pursued in discovering common genetic variants with minor 
effects. A GWAS is typically based upon a large array of genome-wide distributed 
genetic markers such as single-nucleotide polymorphisms (SNPs), yet unlike linkage 
scans the focus does not lie on extended pedigrees but rather on huge cohorts of 
patients that are compared with unaffected subjects (case-control design). 
Remarkably, most GWASs to date have not been successful in discovering variants 
that reached genome-wide significance in terms of an association with ADHD 
(Hinney et al., 2011), underlining the polygenic and multifactorial character of this 
disorder. Nonetheless, such studies have contributed to finding new potential risk 
genes, for example CDH13, which reached high rankings in a reproducible manner 
(Banaschewski et al., 2010).  
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Another genome-wide approach to investigate ADHD-linked genes has recently 
emerged, namely copy number variation (CNV) studies. These analyses help to 
detect micro-duplications and micro-deletions in the genome possibly implicated in 
the pathogenesis of ADHD. Thus far, several CNVs of potential relevance have been 
suggested, including a duplication comprising the gene for the neuropeptide Y (NPY; 
Lesch et al., 2011), a deletion affecting the gene for the metabotropic glutamate 
receptor 5 (GRM5; Elia et al., 2012), and a duplication involving the gene CHRNA7 
which encodes the alpha-7 subunit of the neuronal nicotinic acetylcholine receptor 
(Williams et al., 2012). 
 
Besides these hypothesis-free approaches, there have also been numerous ADHD 
candidate gene association studies in recent years, concentrating on selected genes 
which were supposed to play a role in the disorder, based upon theoretical or 
empirical hints. Among all investigated genetic loci, those closely related to 
monoaminergic neurotransmission were the most frequent. For instance, significant 
association with ADHD was reported for genes of the D4 dopamine receptor (DRD4), 
the D5 dopamine receptor (DRD5),  the dopamine transporter (DAT, SLC6A3), the 
dopamine beta-hydroxylase (DBH), the serotonin transporter (5-HTT, SLC6A4), the 
serotonin 1B receptor (HTR1B) and the synaptosomal associated protein of 25kDa 
(SNAP25; Faraone and Mick, 2010). 
 
1.1.5 Environmental risk factors  
Besides the important influence of heritability on the pathophysiology of ADHD, 
various environmental risk factors are also considered playing a role, including 
certain substances, such as polychlorinated biphenyls (PCBs) and also foetal 
exposure to alcohol or maternal smoking. Moreover, pregnancy and delivery 
complications, a low birth weight as well as psychosocial adversity, e.g. maltreatment 
and emotional trauma, have also been shown to correlate with the disorder (for a 
review see Banerjee et al., 2007).  
 
Besides, it has been suggested that an interplay between genes and environment   
(G × E interaction) may reflect an important cause of phenotypic complexity of 
ADHD. For example, Kahn and colleagues reported an association between a 480-
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bp SLC6A3 risk allele and impulsivity/hyperactivity in children, albeit only when these 
children had been previously exposed to maternal prenatal smoking (Kahn et al., 
2003). 
Therefore, despite the origins of ADHD apparently lying in genes, the course of the 
disorder may be considerably affected by the manner in which these inherited factors 
modulate the response to environmental conditions. 
 
1.1.6 Neurobiology 
Concerning the neurobiology of ADHD, dysregulations of different central 
neurotransmitter systems belong to the major aspects being discussed. These 
concepts initially arose from the observation that many substances known as being 
efficacious in treating ADHD seem to share a common mechanism of action, namely 
an impact on monoaminergic neurotransmission. For instance, this includes the 
aforementioned compounds methylphenidate and atomoxetine, which block the 
dopamine and/or norepinephrine transporter, and the selective serotonin-
norepinephrine reuptake inhibitor venlafaxine (Muth et al., 1986). 
 
A multitude of insights has been gained via structural neuroimaging studies in search 
of neuroanatomical correlates of ADHD. Among other things, it could be shown that 
overall brain volumes of children with ADHD were consistently reduced in 
comparison to healthy controls throughout childhood and adolescence (Castellanos 
et al., 2002). More precisely, decreased volumes were reported for brain regions 
such as cerebellum, frontal cortex and basal ganglia, with the latter two regions also 
found to exhibit alterations in structural symmetry (for a review, see Krain and 
Castellanos, 2006). In a meta-analysis conducted by Frodl and Skokauskas, further 
regions were described as being volumetrically different in ADHD patients, including 
the anterior cingulated cortex and the amygdala (Frodl and Skokauskas, 2012). 
 
In parallel to these structural findings, ADHD patients were also found to display 
functional anomalies in particular parts of their brain. A consistent pattern of 
dysfunction could be discovered by means of neuropsychological approaches and 
functional imaging techniques such as single photon emission computed tomography 
(SPECT), functional magnetic resonance imaging (fMRI), positron emission 
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tomography (PET) or electroencephalography (EEG), not only in prefrontal and 
dorsal anterior cingulate cortex but also in striatal parts like the caudate and putamen 
as well as in other regions such as the parietal cortex, thalamus and cerebellum (for 
a review, see Bush et al., 2005). 
 
Based on these and other findings, it has been suggested that ADHD is 
accompanied by dysfunctions of frontal–striatal–cerebellar circuits, resulting in 
distinctive intermediary traits. Rather known as ‘endophenotypes’ and located at the 
level between gene function and behaviour, these heritable traits are thought to 
constitute objective quantitative parameters, possibly helping to predict an 
individual’s risk of developing the characteristic behavioural symptoms of a disorder. 
In terms of ADHD, deficits in response inhibition, temporal processing and working 
memory, as well as shortened delay gradients are discussed as promising 
endophenotypes (for a review, see e.g. Rommelse, 2008). 
 
1.1.7 Animal models         
Animal models can be valuable when investigating human phenomena as they 
provide certain advantages. For instance, they allow a large variety of interventions, 
often display a high degree of genetic homogeneity and can be assessed in a 
controlled environment. However, an animal model should be reasonably similar to 
human cases with regard to behaviour, physiology, symptomatology and treatment. 
To estimate their validity, animal models of human mental disorders typically are 
evaluated based on three criteria, namely construct validity, face validity and 
predictive validity (Willner, 1986). While construct validity refers to the model’s 
theoretical rationale, face validity describes the ability to mirror the basic behavioural 
characteristics of the disorder and predictive validity assesses the model’s efficiency 
in predicting certain aspects of the disorder, for example with regards to 
pharmacological treatment.  
 
Various potential animal models of ADHD have been developed and described in the 
literature in recent decades. Despite several of these models not meeting all three 
validation criteria, at least face validity is a very common feature, and especially in 
terms of hyperactivity. Beyond that, many models show predictive validity in terms of 
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treatment with ADHD drugs. However, construct validity is only insufficiently fulfilled 
by many animal models of ADHD, not least due to the complex pathology of ADHD 
(Kostrzewa et al., 2008).  
Irrespective of validity, animals proposed as ADHD models can be divided into 
subcategories, depending on the method used to generate them. For instance, there 
are some animal models of ADHD – in this case rat models – that were produced by 
physical trauma, such as x-radiation (Gazzara and Altman, 1981) or hypoxia 
(Gramatte and Schmidt, 1986), while other ADHD models were obtained via 
pharmacological interventions, for example exposure to lead, cadmium or 6-
hydroxydopamine during early stages of development (Kostrzewa et al., 2008). 
However, many of these models only partially mimic ADHD symptoms, or are so 
remote from ADHD etiology that they did not attract significant publicity. 
Another subcategory of potential ADHD models - and maybe the most popular - 
comprises animals with genetic peculiarities. One of the most widely studied animal 
models for ADHD is the Spontaneously Hypertensive Rat (SHR) which was obtained 
by inbreeding the Wistar-Kyoto (WKY) strain. Besides high blood pressure, these rats  
also display ADHD-like symptoms, in terms of increased impulsivity, lack of attention 
and hyperactivity with this latter symptom shown to be ameliorated by treatment with 
ADHD drugs (Sagvolden, 2000). Furthermore, frequently used genetic ADHD models 
include the Dat/Slc6a3 knockout Mouse which was developed by targeted genetic 
engineering, as well as the Coloboma Mutant Mouse, produced as a product of 
neutron irradiation and exhibiting mutations which include the gene Snap25. Both of 
these murine ADHD models were shown to fulfill face validity as well as predictive 
validity criteria (for a review, see Arime et al., 2011).  
 
1.2 Glucose transporters 
The monosaccharide glucose constitutes one of the most important molecules in the 
energy metabolism of nearly every organism, acting as a substrate for both catabolic 
and anabolic processes. Given that plasma membranes are impermeable for 
hydrophilic molecules, the transport of glucose from extracellular fluid into the cell 
requires the presence of particular transporter proteins.  
Two glucose transporter families can essentially be distinguished: on the one hand, 
the group of sodium glucose-linked transporters (SGLTs), which belong to the 
 Introduction 
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SLC5A gene family and mediate the secondary active co-transport of glucose; and 
on the other hand, the group of facilitative glucose transporters (GLUTs), encoded by 
the SLC2A gene family and enabling the passive diffusion of glucose into a cell.  
 
1.2.1 The SLC2A family of glucose transporters (GLUTs) 
In the majority of mammalian tissues, glucose uptake is mediated via glucose 
transporters of the GLUT protein family, which belongs to the Major Facilitator 
Superfamily (MFS) of membrane transporters (Pao et al., 1998). At present, the 
GLUT protein family is known to comprise 14 isoforms, each displaying particular 
properties in terms of kinetics, substrate specificity and tissue expression. However, 
members of this family also share several common features given that they all 
facilitate the bidirectional energy-independent transport of glucose and/or other 
hexoses, and all are characterised by twelve transmembrane spanning helices and 
an oligosaccharide side chain located either on the first or fifth extracellular loop (see 
Figure 1). 
 
 
 
Fig. 1: Schematic illustration of a facilitative glucose transporter 
Displayed are the characteristic 12 transmembrane segments, connected by intra- and extracellular loops that can exhibit 
oligosaccharide side chains (sugar moieties). The amino- (NH2) and the carboxy-terminus (COOH) are both located 
intracellularly. The image includes a homology plot between GLUT1 and GLUT4, with amino acid residues being unique to 
GLUT4 highlighted in red [adapted from Bryant et al., 2002]. 
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Based on similarities of primary sequence, three subclasses of glucose transporters 
can be distinguished. Class I includes the ‘classical’ isoforms GLUT1-4 and GLUT14, 
which is a highly similar paralog of GLUT3. Class II comprises the ‘odd’ transporters 
GLUT5, 7, 9 and 11, while class III involves the even number isoforms (GLUT6, 8, 10 
and 12) as well as the proton-dependent myoinositol transporter HMIT (GLUT13) 
(see Figure 2). 
 
 
 
Fig. 2: Overview of the family of facilitative glucose transporters  
Based on sequence similarities, the 14 members of this family can be subdivided into 3 different classes [adapted from  
Augustin, 2010]. 
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1.2.2 The glucose transporter GLUT3 
As implied by its name, the protein GLUT3, which is encoded by the gene SLC2A3, 
was the third glucose transporter isoform to be cloned (Kayano et al., 1988). The 
human gene is located at the short arm of chromosome 12, with a size of 
approximately 17 kb. Currently, the database Ensembl (www.ensembl.org) lists 
eleven human SLC2A3 mRNA transcripts, although only two are described as 
protein-coding. The first of these two transcripts contains all ten exons of the gene 
and leads to a protein of 496 amino acids (53.9 kDa), whereas the other only 
includes parts of the coding sequence (4 exons), thus producing a 142 amino acid 
protein (15.0 kDa).  
 
SLC2A3 was shown to be expressed in various peripheral tissues such as placenta 
and kidney (Kayano et al., 1988), and also in skeletal muscle (Stuart et al., 1999), 
white blood cells (Mantych et al., 1992) and testis (Haber et al., 1993). However, the 
gene is predominantly known for its high expression in the brain, where GLUT3 is 
suggested to constitute the main neuronal glucose transporter, thus assuring the 
extensive energy supply of these cells (Kayano et al., 1988; Nagamatsu et al., 1992; 
Vannucci et al., 1997). 
 
At the subcellular level, GLUT3 is primarily located in the plasma membrane, i.e. the 
cell surface. However, in certain cell types considerable amounts of this protein were 
found enclosed by intracellular vesicles. In 1997, for example, Heijnen and 
colleagues reported on the appearance of GLUT3 in α-granule membranes of 
platelets (Heijnen et al., 1997). Within neurons and PC12 cells, the transporter was 
described as located within a distinct homogenous population of synaptic-like 
vesicles (Thoidis et al., 1999). In both cases, it was suggested that GLUT3 is stored 
within these intracellular membranes until eventually being translocated to the 
cellular surface.  
 
From a structural perspective, GLUT3 essentially displays the characteristic features 
of a class I glucose transporter, among others 12 transmembrane domains (TM) and 
a long extracellular loop between TM1 and 2, including a glycosylation site. However, 
compared to other class I facilitative glucose transporters, GLUT3 was shown to 
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exhibit a quite low Km value for glucose, implicating a strong affinity for this particular 
carbohydrate (for a review, see Simpson et al., 2008). Nevertheless, glucose is not 
the only molecule conveyed by GLUT3 as some other hexoses and closely related 
compounds, such as galactose, mannose or dehydroascorbic acid also serve as 
adequate substrates (Gould et al., 1991; Rumsey et al., 1997). 
 
1.2.3 Clinical background of SLC2A3 
Recent animal and human studies have suggested that SLC2A3 plays a role in 
several psychiatric disorders. In 2008, Liu and colleagues reported on a correlation 
between decreased central levels of GLUT3 and histopathological indications of 
Alzheimer disease, such as hyperphosphorylation of tau protein in the human brain 
(Liu et al., 2008). Furthermore, a genome-wide expression analysis in schizophrenia, 
published in 2009, revealed several genes - amongst others SLC2A3 - whose 
expression was significantly altered in the patient group (Kuzman et al., 2009). The 
authors of another genome-wide scan, in this case concerning dyslexia, concluded 
that a two-marker haplotype which could be associated with a particular 
neurophysiological endophenotype of dyslexia had a transregulatory impact on 
SLC2A3 expression (Roeske et al., 2011). 
A rodent study focusing on mice heterozygously deficient for Slc2a3, listed some 
behavioural peculiarities including that these genetically modified mice were found to 
exhibit perturbed cognitive flexibility, impaired social behaviour and reduced 
vocalization at low-frequency, as well as stereotypic behaviours in certain 
environmental conditions. Based on these observations, the authors suggested that 
Slc2a3 haploinsufficiency in mice leads to characteristic features, resembling 
symptoms typically found in patients with autism spectrum disorders (Zhao et al., 
2010). 
 
In addition, SLC2A3 was identified by two unrelated genome-wide copy number 
variation (CNV) scans, both initiated in order to discover micro-duplications and 
micro-deletions potentially implicated in certain psychiatric disorders. While the first 
study analysed a three-generation Old Order Amish pedigree with the focus on 
affective disorders (Yang et al., 2009), the latter was conducted in a cohort of 
European ADHD patients (Lesch et al., 2011). Interestingly, both studies detected a 
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duplication on chromosome 12p13.31, which is known as a common CNV in the 
general population. The duplicated chromosomal region has a size of approximately 
130kb, and encompasses the entire gene locus of SLC2A3 and the pseudogene 
NANOGP1 as well as the anterior exons of SLC2A14. 
A significant excess of SLC2A3 duplication carriers was found in a subsequent 
analysis of a German population sample (251 childhood and 675 adult ADHD cases 
vs. 767 controls): while 4.9% of cases displayed this CNV, it was only 2.6% of 
subjects in the control group (Merker et al., manuscript in preparation). Moreover, the 
same study showed that the T-allele of the SNP rs12842, which is located within the 
3’UTR of the SLC2A3 gene, is significantly associated with ADHD in an analysis of 
four European population samples. 
 
1.3 Latrophilins 
1.3.1 Discovery 
Latrophilins were originally discovered as receptors for α-latrotoxin (α-LTX), a potent 
neurotoxin and component of the black widow spider (Latrodectus mactans) venom 
(Davletov et al., 1996; Krasnoperov et al., 1997), which exerts its toxic effects by 
inducing a massive release of neurotransmitters and hormones from various 
secretory cells in vertebrates (Grishin, 1998). 
 
Besides latrophilins, two other proteins were found to bind this toxin specifically: 
neurexins and protein tyrosine phosphatase σ (Ushkaryov et al., 1992; Krasnoperov 
et al., 2002). Despite the mechanism of action being complex and thus still subject of 
research, it has been known for many years that α-LTX-triggered neuronal exocytosis 
can occur both in the presence and in absence of extracellular Ca2+-ions, although 
not in absence of toxin-specific receptors (for a review, see Ushkaryov et al., 2008).  
Given that Ca2+-influx is not required for latrophilin-mediated toxic effects, latrophilins 
are also referred to as Ca2+-independent receptors of α-LTX (CIRLs) or as 
Lectomedins – a term derived from the names of certain protein domains in these 
receptors (see description below). 
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1.3.2 Latrophilin family 
Three latrophilin homologs can be distinguished in human (latrophilin-1, -2 and -3), 
encoded by the genes LPHN1, 2 and 3 at chromosome 19, 1 and 4, respectively.  
The three members of this family exhibit a notable rate of sequence homology that 
gives rise to a very similar protein structure. However, it has been suggested that 
latrophilin proteins of the same type from different animal species show higher rates 
of identity than different latrophilin homologs within the same species which is 
indicative of a considerable level of specialisation (Matsushita et al., 1999). 
According to the database Ensembl (www.ensembl.org), latrophilin orthologs can be 
found in more than 40 different animal species including not only mammals such as 
chimpanzees, mice or dogs but also members of other biological classes, such as 
amphibians, reptiles, birds, fishes and nematodes. A very common characteristic of 
the family of latrophilins is the presence of multiple splicing sites which result in 
different protein variants, exhibiting modifications in several intra- and extracellular 
domains (Matsushita et al., 1999). 
However, the members of the latrophilin family show considerable differences 
concerning their interaction with α-LTX: while latrophilin-1 binds the toxin with 
comparatively high affinity, latrophilin-2 and latrophilin-3 display only weak 
intermolecular interaction, if at all (Sugita et al., 1998; Ichtchenko et al., 1999). 
 
1.3.3 Expression 
The majority of published data about latrophilin expression arises from experiments 
with human and rat tissue, namely species that exhibit three different latrophilin 
homologs. Lphn1 was shown to be expressed highly in the brain, and to a lesser 
extent, in other tissues, for example lung, kidney and spleen (Sugita et al., 1998; 
Matsushita et al., 1999). By contrast, Lphn2 tissue expression appears to be much 
more universal and widespread. Furthermore, it was found preferentially outside of 
the brain, and particularly in lung, liver and placenta (Ichtchenko et al., 1999). While 
most tissue-specific expression was displayed by Lphn3, which could be detected 
particularly in the brain, the absolute amounts of Lphn3 transcript in rat brain were 
apparently lower than those of Lphn1 (Matsushita et al., 1999). In humans, LPHN3 
mRNA showed a non-uniform distribution within the brain, preferentially occurring in 
regions such as the amygdala, cerebellum and cerebral cortex, indicative of a high 
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level of functional specialisation (Arcos-Burgos et al., 2010). A comparable 
expression pattern can be found in mouse brain with high Lphn3 mRNA levels in 
regions such as the cerebral cortex, hippocampus and cerebellum (see Figure 3). 
 
 
Fig. 3: Lphn3 in situ hybridisation of a sagittal mouse brain slice (expression mask image) 
Lphn3 gene expression is highlighted based upon the following heat map colour scale: 
 
The brain regions with prominent Lphn3 gene expression include the cerebral cortex (CTX), the olfactory bulb (OB) and the 
cerebellum (CB), as well as some divisions of the hippocampus (HIP), especially the CA1 layer and the dentate gyrus (DG) 
[adapted and modified from Allen Brain Atlas, www.brain-map.org].  
 
1.3.4 Protein structure 
Latrophilins are integral membrane proteins that belong to the prominent group of G 
protein-coupled receptors (GPCRs): a superfamily which comprises more than 800 
members (Katritch et al., 2012). Despite latrophilins exhibiting the common GPCR-
topology of 7 transmembrane spanning α-helices, they still substantially differ from 
most other members of this protein family in terms of their peculiar domains (see 
Figure 4).  
 
The intracellular (i.e. carboxy terminal) region of latrophilins contains multiple 
potential sites for phosphorylation and palmitoylation which are presumably involved 
in the modulation of receptor activity. Moreover, various PEST sequences (rich in 
proline, glutamic acid, serine and threonine) can be found (Matsushita et al., 1999). 
HIP 
CTX 
CB 
CA1 
DG OB 
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Latrophilins are confined to the plasma membrane via seven hydrophobic trans-
membrane segments (TMs), resembling those found in secretin/calcitonin GPCRs: a 
family of receptors whose members often bind peptide hormones and are implicated 
in secretory processes (Lelianova et al., 1997). 
 
The extracellular (i.e. amino-terminal) division of a latrophilin receptor includes motifs 
with remarkable sequence similarity to rather uncommon molecules, for instance a 
rhamnose binding lectin-like domain and an olfactomedin-like domain.  
 
 
Fig. 4: Schematic illustration of the general latrophilin protein structure 
The protein essentially consists of a long extracellular part connected to the intracellular latrophilin tail (LPHN) via seven 
transmembrane helices. Among others, the extracellular part comprises a sea urchin egg lectin-like (SUEL) domain, an 
olfactomedin-like domain and a GPCR proteolysis site (GPS), as well as a homology region (HR) shared with brain-specific 
angiogenesis inhibitors [adapted from Domene et al., 2011]. 
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While the first was originally described as a protein domain in eggs of sea urchins, 
playing a role for monosaccharide recognition (Ozeki et al., 1991), the latter is known 
from olfactomedins, a multifaceted family of secreted glycoproteins likely implicated 
in mechanisms such as chemoreception (Snyder et al., 1991). Moreover, the 
extracellular division of latrophilins exhibits a homology region shared with brain-
specific angiogenesis inhibitors, with these molecules constituting another family of 
GPCRs, comprising three members (BAI1, 2 and 3) and possibly playing a role in the 
suppression of glioblastoma (Shiratsuchi et al., 1997). On the other hand, the 
extracellular latrophilin division exhibits both a hormone receptor domain and a short 
cysteine-rich sequence, thus two motifs also shared by other GPCRs (Perrin et al., 
1998; Sugita et al., 1998). Importantly, the cysteine-rich domain comprises a GPCR 
proteolysis site (GPS) located approximately 20 amino acids upstream of the first 
transmembrane segment. Cleavage at this site gives rise to two fragments: an 
extracellular amino-terminal subunit and a (smaller) carboxy-terminal subunit 
confined to the membrane. According to their approximate molecular weight [kDa] 
observed during electrophoresis, the first fragment was termed p120 and the latter 
p85 (Krasnoperov et al., 1997). 
Like other GPCRs containing such a proteolysis site, latrophilins were suggested to 
undergo proteolytic processing in the endoplasmic reticulum. After cleavage, the two 
resulting subunits were demonstrated as remaining non-covalently bound to each 
other at the cell surface although, they can also dissociate again under certain 
conditions (Krasnoperov et al., 2009). Remarkably, upon binding of α-LTX to the 
p120 fragment, both subunits reassemble and induce intracellular signalling 
cascades (Silva et al., 2009). 
 
1.3.5 Functions 
Given that the p120 subunit of latrophilins contains several motifs that were 
demonstrated as participating in cell adhesion processes (for instance the lectin-like 
domain and the olfactomedin-like domain), latrophilins are considered part of a 
subgroup of GPCRs: the so-called adhesion GPCR family (Fredriksson et al., 2003). 
Members of this family are regarded as naturally occurring chimeras of cell adhesion 
molecules and signaling receptors, which are possibly able to convert cell–cell 
interactions into intracellular signals (Martinez et al., 2011). 
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Like other GPCRs, latrophilins were shown to interact with intracellular G proteins – a 
prominent family of molecules implicated in transmitting signals from the outside to 
the inside of a cell. In 1997, Lelianova and colleagues reported that latrophilin-1 
could be co-purified with the heterotrimeric G protein subunit Gαo in brain extracts of 
rat and cow and also described that α-LTX-induced synthesis of the secondary 
messenger molecules inositol trisphosphate (IP3) and cAMP is notably increased in 
COS cells transfected with latrophilin-1 (Lelianova et al., 1997). Furthermore, these 
results were confirmed and supplemented by another group, who found that 
latrophilin signaling was not only linked to Gαo but also to Gαq/11, namely a subunit 
known to induce phospholipase C-mediated intracellular signal transduction 
pathways (Rahman et al., 1999). Important insights were also achieved concerning 
the potential physiological role of latrophilins by a study focusing on the arrangement 
of cell division planes during early embryogenesis of C. elegans. By interacting with a 
mitotic spindle orientation pathway, latrophilin-1 was shown to exert a remarkable 
influence on the anterior–posterior tissue polarity of the embryo, with the Lectin-like 
latrophilin domain found to be particularly important for this function (Langenhan et 
al., 2009). 
 
On the other hand, much effort has been applied towards discovering endogenous 
ligands of latrophilins during the past decade. Via affinity chromatography of the 
extracellular division of latrophilin-1, Silva and colleagues were successful in isolating 
a protein from rat brain extracts which they termed Lasso. This protein was found to 
constitute a splice variant of teneurin-2 known as a brain-specific orphan cell surface 
receptor implicated in processes such as synaptogenesis and neuronal pathfinding. 
In addition, this workgroup was able to prove that latrophilin-1 and Lasso form 
transsynaptic complexes capable of inducing presynaptic signal pathways (Silva et 
al., 2011).  
Shortly after, Boucard and colleagues surprisingly reported on a binding interaction 
between latrophilin-1 and neurexins, which (as previously mentioned) also belong to 
the group of α-LTX binding proteins. In this study, it was found that the olfactomedin-
like domain of latrophilin-1 forms transsynaptic adhesion complexes with neurexins, 
thus suggesting that both receptors are part of the same molecular pathway 
(Boucard et al., 2012).  
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While nothing is yet known about potential ligands for latrophilin-2, new insights have 
been gained regarding the third homolog. In 2012, a study was published 
demonstrating that FLRT3, a molecule belonging to the family of fibronectin leucine-
rich repeat transmembrane proteins with supposed functions in cell migration and 
axon guidance, is a specific endogenous ligand for latrophilin-3 (O'Sullivan et al., 
2012). Indeed, the authors provided evidence for a strong transsynaptic binding 
interaction between the ectodomains of both proteins, also finding that manipulations 
targeting these complexes gave rise to significantly reduced glutamatergic synapse 
densities in cultivated neurons.  
 
1.3.6 Clinical background 
Latrophilin genes, and especially LPHN3, have received increasing attention within 
clinical research in recent years. The gene coding for latrophilin-3 has been 
suggested as being involved in a wide range of pathological conditions such as brain 
ischemia (Bin Sun et al., 2002), addiction (Liu et al., 2006), cancer (Kan et al., 2010), 
dyslexia (Field et al., 2013) and autism (Gau et al., 2012). 
 
Moreover, LPHN3 has also been investigated in the context of the psychiatric 
disorder ADHD. In 2010, Arcos-Burgos and colleagues published the results of a 
genetic linkage analysis conducted for a South American population isolate on the 
basis of microsatellite markers, with subsequent fine-mapping of targeted regions 
and the examination of several American and European population samples. The 
study revealed a risk haplotype in the LPHN3 gene (chromosomal location: 4q13.2) 
that was significantly associated with ADHD (Arcos-Burgos et al., 2010). Moreover, it 
could be demonstrated that this LPHN3 susceptibility haplotype was accompanied by 
histological and functional changes including an inverse correlation between the 
dosage of the haplotype and the neuronal number in brain regions of the frontal–
striatal–cerebellar circuit, as assessed by the ratio of N-acetylaspartate to creatine 
(Arcos-Burgos et al., 2010). When undergoing neurophysiological tasks of cognitive 
response control, homozygous haplotype carriers were also found to make more 
omission errors and show less NoGo-Anteriorisation which represents a marker of 
prefrontal functioning (Fallgatter et al., 2012). 
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Beyond these human studies, some ADHD-related publications have also analysed 
the role of latrophilin-3 orthologs in other animals. For instance, the corresponding 
gene lphn3.1 was found to exert a considerable influence on the distribution and 
number of dopaminergic neurons in the ventral diencephalon of zebrafish (Lange et 
al., 2012). Additionally, the authors showed that a loss of lphn3.1 function led to a 
hyperactive/impulsive phenotype in zebrafish, which interestingly could be rescued 
by methylphenidate and atomoxetine, namely two drugs efficacious in treating 
ADHD. 
On the other hand, a recent study with Lphn3 mutant mice generated on the basis of 
gene-trap mutagenesis reported that a lack of Lphn3 gene function gave rise to a 
number of phenotypical peculiarities (Wallis et al., 2012). Among other things, these 
mutant mice displayed altered expression levels for several genes well-known from 
monoaminergic systems, as well as neurochemical changes in terms of increased 
serotonin and dopamine amounts in the dorsal striatum. Significantly, Lphn3 mutant 
mice exhibited higher locomotor activity in the open field test than wildtype mice, both 
under normal conditions and following the application of a stimulant drug (cocaine). 
 
1.4 Goals of this thesis 
There is a notable social, scientific and economic interest in broadening the 
understanding and refining the treatment of mental disorders, given that they can 
have severe impacts on the lives of affected patients and their families. One of the 
most frequent psychiatric disorders, and particularly during childhood and 
adolescence, is the neurodevelopmental syndrome ADHD. Despite the complex and 
insufficiently understood mechanisms involved in its etiology, ADHD has long been 
known as a highly heritable disorder, which has prompted an intensive search of risk 
genes. Several genome-wide screenings focusing on ADHD were conducted in 
recent years, leading to the identification of numerous polymorphisms at different 
genetic loci, thus underlining the polygenic nature of this disorder. The list of detected 
polymorphisms included some located within the gene SLC2A3, coding for the 
glucose transporter isoform 3, and the gene LPHN3, encoding the latrophilin isoform 
3. 
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Accordingly, the present thesis will focus on these two genes, albeit with different 
approaches:  
 
In the first case, the role of SLC2A3 polymorphisms (SNP and CNV) will be 
investigated in human. For this purpose, methods such as functional EEG 
measurements, gene expression analyses and cellular glucose uptake assays will be 
applied. The latter two methods will involve two easily available peripheral cell 
models: lymphoblastoid cell lines (LCLs) and native peripheral blood mononuclear 
cells (PBMCs).  
The overall aim of all such methods is to elucidate the molecular and functional 
consequences arising from SLC2A3 variants, with particular attention paid to the 
aforementioned duplication of this gene. Carriers of this duplication are expected to 
show gene dose-dependent elevated SLC2A3 expression (~50%) on RNA and 
protein level, implicating higher cellular transport of glucose and consequently 
functional anomalies in the brain such as altered prefrontal activity. 
 
With regards to LPHN3, the corresponding ortholog in mouse (Lphn3) will be 
investigated via the generation of a new genetically modified mouse model with 
conditional knockout potential.  
In contrast to the aforementioned Lphn3 gene-trap mice (Wallis et al., 2012) which 
lack the gene in a constitutive-like manner, a conditional Lphn3 knockout involves the 
advantage of latrophilin-3 deficiency being restricted to a particular cell type or a 
particular developmental stage, which might allow a more precise and compelling 
interpretation of the resulting phenotype. Based on the reported findings for different 
animal models of latrophilin-3 deficiency, it is expected that conditional Lphn3 
knockout mice show alterations in monoaminergic - especially dopaminergic - 
systems, and behavioural peculiarities resembling those traits typically observed in 
human ADHD patients. 
 
Despite merely constituting small pieces within the huge puzzle of ADHD genetics, 
the expected results of theses analyses should contribute to the knowledge 
concerning the physiological and pathophysiological role of SLC2A3 and LPHN3. 
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2 Material and Methods 
2.1 Material 
2.1.1 SLC2A3 
Human samples 
CNV gene expression analysis and cellular glucose uptake assay: For these cell 
culture-based experiments, participants with two gene copies (= control subjects) and 
with three copies (= duplication carriers) were recruited.  
EBV-infected lymphoblast cell samples were part of a randomised population kindly 
provided by the workgroup of Prof. Dr. Clemens Müller-Reible (Department of Human 
Genetics, University of Würzburg). Among these were 15 control and 6 duplication 
samples, all deriving from subjects without any known psychiatric history. The 
remaining lymphoblast samples with SLC2A3 duplication were obtained by means of 
blood samples from patients of the Department of Psychiatry in Würzburg (among 
these 8 ADHD patients and 2 patients with bipolar disorder). Since diagnostic status 
of duplication carriers did not turn out to have a notable influence on SLC2A3 gene 
expression results, respective data were pooled. 
On the other hand, native peripheral blood mononuclear cell (PBMC) samples were 
collected at the Department of Psychiatry in Würzburg. All respective duplication 
carriers were ADHD patients of the KFO125 Clinical Research Unit, whereas the 
control group with two gene copies consisted of healthy participants as well as ADHD 
patients. Again, diagnostic status did not exert a notable effect on SLC2A3 gene 
expression so that data of control samples were pooled. 
 
Functional EEG measurements: 144 adult ADHD in- and outpatients at the 
Department of Psychiatry in Würzburg (among these 38 rs12842 T-allele carriers) as 
well as 71 healthy controls (among these 14 rs12842 T-allele carriers) were recruited.  
On the other hand, 9 ADHD patients with SLC2A3 duplication were compared to 9 
ADHD patients with normal copy number. These groups were carefully matched with 
regard to age, gender, smoking status, handedness, medication and ADHD subtype-
diagnosis. Additionally, two healthy control groups were analyzed, each exhibiting a 
size of 5 persons. One of these groups comprised duplication carriers and the other 
                                                                                                     Material and Methods 
___________________________________________________________________________________________________________________________________________________________________                                                 
22 
one subjects with a copy number of 2. Again, groups were thoroughly matched in 
terms of the above-mentioned criteria (excluding medication and ADHD diagnosis).  
 
SLC2A3 genotyping 
Product / Device Manufacturer 
TaqMan Copy Number Assay for SLC2A3 (Hs04406005_cn) Applied Biosystems 
TaqMan RNase P Control Reagents Kit Applied Biosystems 
C1000 Thermal Cycler incl CFX384 Real-Time System Bio-Rad 
CopyCaller, version 1.0 Applied Biosystems 
BAC clone RP11-277E18 BACPAC Resources 
A1 epifluorescence microscope Zeiss 
FISHView EXPO, version 2.0 Applied Spectral Imaging 
QIAquick PCR Purification Kit  Qiagen 
BioPrime Array CGH Genomic Labeling System Invitrogen 
4000B scanner Axon Instruments 
Genepix, version 5.0 Axon Instruments 
iPlex SNP assay Sequenom 
Autoflex mass spectrometer Bruker Daltonics 
 
Lymphoblast cell culture 
Medium Content Manufacturer 
Lymphoblast culture medium RPMI 1640 Medium 
17.5% HI FBS 
1% L-Glutamine 200mM 
1% Gentamicin 50mg/ml 
Invitrogen 
Invitrogen 
Invitrogen 
Invitrogen 
 
Product / Device Manufacturer 
Ficoll-Paque Plus  GE Healthcare 
RNAprotect Cell Reagent  Qiagen 
Leucosep 12 ml Tube Greiner 
Cellometer SD100 Counting Chambers Nexcelom Bioscience 
Cellometer Auto T4 cell counter  Nexcelom Bioscience 
 
RNA extraction and quantitative reverse transcription (qRT) PCR 
Product / Device Manufacturer 
RNeasy Plus Mini Kit Qiagen 
Experion automated electrophoresis station Bio-Rad 
iScript cDNA Synthesis Kit Bio-Rad 
NanoDrop ND-1000 Spectrophotometer Peqlab 
iQ SYBR Green Supermix Bio-Rad 
C1000 Thermal Cycler incl CFX384 Real-Time System Bio-Rad 
Bio-Rad CFX Manager Bio-Rad 
GeNorm, version 3.5 Ghent University Hospital 
LinRegPCR, version 11.1 Academic Medical Center 
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Primer Sequence Manufacturer 
SLC2A3 qRT forward  5'-GGGTATGATCGGCTCCTTTT-3' Metabion 
SLC2A3 qRT reverse  5'-GCATTTCAACCGACTTAGCTACT-3' Metabion 
HS_GAPDH_2_SG Trade secret Qiagen 
HS_PGK_1_SG Trade secret Qiagen 
HS_B2M_1_SG Trade secret Qiagen 
HS_ALAS1_1_SG Trade secret Qiagen 
 
Protein extraction and Western blotting 
Solution Content Manufacturer 
External chamber buffer 5% NuPAGE MOPS SDS Running buffer Invitrogen 
Internal chamber buffer External chamber buffer  
0.25% NuPAGE Antioxidant  
in-house production 
Invitrogen 
Loading buffer 5µl NuPAGE LDS Sample buffer 
2µl NuPAGE Sample reducing agent 
Xµl protein lysate (10µg) 
13 – Xµl ddH20 
Invitrogen 
Invitrogen 
 
 
Transfer buffer 5% Nupage Transfer Buffer 
10% Methanol 
0.1% NuPAGE Antioxidant 
Invitrogen 
Merck 
Invitrogen 
Stripping buffer 3mM SDS  
200mM Glycine  
1% Tween 20  
0.1% NuPAGE Antioxidant, pH 2.2 
AppliChem 
Fluka 
Sigma-Aldrich 
Invitrogen 
 
Product / Device Manufacturer 
Complete Mini EDTA-free Protease Inhibitor Cocktail Tablets Roche 
BCA Protein Assay Thermo Scientific 
Novex Sharp Protein Standard Invitrogen 
Nitrocellulose Paper Sandwich 0.45µm pore size Invitrogen 
NuPAGE 4-12% Bis-Tris Gels, 1.0 mm Invitrogen 
ECL Prime GE Healthcare 
Multiskan Spectrum Microplate Spectrophotometer Thermo Labsystems 
ChemiDoc system Bio-Rad 
Quantity One, version 4.6.8 Bio-Rad 
Aida 2D Densitometry, version 2.0 Raytest Isotopenmessgeräte 
Multiskan Spectrum, version 1.0 Thermo Labsystems 
 
Antibodies Final concentration Manufacturer 
Rabbit Anti-GLUT3 [ab15311] 1/400 Abcam 
Goat anti-rabbit IgG-HRP [sc-2054] 1/7500 Santa Cruz 
Mouse anti-beta-actin (HRP) [ab20272] 1/10000 Abcam 
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Cellular glucose uptake assay 
Product / Device Manufacturer 
2-Deoxy-D-Glucose-1,2-3H(N), Specific Activity: 5-10Ci/mmol Perkin Elmer 
Cytochalasin B AppliChem 
RPMI 1640 Medium, no Glucose Invitrogen 
Rotiszint eco plus Roth 
LS6500 Multipurpose Scintillation Counter Beckman Coulter 
 
Functional EEG measurements 
Device / Software Manufacturer 
32-channel DC BrainAmp amplifier Brain Products 
Brain Vision Recorder, version 1.01 Brain Products 
Vision Analyzer Brain Products 
 
2.1.2 Lphn3 
Lphn3 targeting vector 
Product Manufacturer 
Lphn3 Knockout-First Targeting Vector (47572) Helmholtz Center Munich 
OneShot TOP10F´ Chemically Competent E. coli Invitrogen 
Endofree Plasmid Maxi Kit Qiagen 
Restriction endonuclease AsiS I New England Biolabs 
 
Murine embryonic stem (ES) cell culture 
Medium Content Manufacturer 
ES cell medium Knockout DMEM Medium 
1% L-Glutamine 200 mM (GlutaMAX) 
0.2% Beta-mercaptoethanol 50mM 
100U/ml Leukemia Inhibitory Factor (LIF)  
15% HI FBS 
1% Penicillin Streptomycin (Pen Strep) 
Invitrogen 
Invitrogen 
Invitrogen 
Millipore 
Invitrogen 
Invitrogen 
SNL cell medium DMEM High Glucose Medium 
10% HI FBS 
1% MEM Non-Essential Amino Acids Solution 
1% Penicillin Streptomycin (Pen Strep) 
Invitrogen 
Invitrogen 
Invitrogen 
Invitrogen 
Trypsin solution PBS 
0.25% Trypsin Solution 
1% Chicken Serum 
0.2g/L EDTA 
1g/L D-Glucose  filter-sterilised (0.22µm) 
Lonza 
Invitrogen 
Invitrogen 
Sigma 
Sigma 
Cell lysis buffer 100mM Tris, pH 8.5 
5mM EDTA, pH 8.0 
0.2% SDS  
200mM NaCl  
100µg/ml Proteinase K 
Roth 
AppliChem 
AppliChem 
Sigma-Aldrich 
AppliChem 
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Product Manufacturer 
JM8A3.N1 mouse embryonic stem cells Sanger Institute 
SNL 76/7 mouse fibroblast STO cell line Sanger Institute 
Mouse ES Cell Nucleofector Kit Amaxa 
Lookout Mycoplasma PCR Detection Kit Sigma 
 
PCR 
Primer Vector construct specificity Sequence Manufacturer 
5’ FRT site forward - 5'-AAACGTAGGCAAGTAATTCACAAAA-3' Metabion 
5’ FRT site reverse Binds only within construct 5'-CCCAACCCCTTCCTCCTACATAGT-3' Metabion 
3’ FRT site forward Binds only within construct 5'-GGGTACCGCGTCGAGAAGTTC-3' Metabion 
3’ FRT site reverse - 5'-AGGACTTTACACACTTTGGCTTTTC-3' Metabion 
3’ loxP site forward - 5'-TCCGGGCACAGACGTCATCAT-3' Metabion 
3’ loxP site reverse Binds only within construct 5'-GGCGAGCTCAGACCATAACTTC-3' Metabion 
5’ long-range forward - 5'-CAGGTCTGGCAAATGGATGTTACAC-3' Metabion 
5’ long-range reverse Binds only within construct 5'-CCCAACCCCTTCCTCCTACATAGT-3' Metabion 
3’ southern probe forward - 5'-ATCCTCCCTCCAAACCCCATGT-3' Metabion 
3’ southern probe reverse - 5'-GGAACAGAAAGGTGGCACAACAGT-3' Metabion 
 
Product Manufacturer 
dNTPs (2.5mM) Promega 
Taq DNA polymerase in-house production 
iProof DNA polymerase Bio-Rad 
GeneRuler 100bp Plus DNA Ladder Fermentas 
GeneRuler 1kb DNA Ladder Fermentas 
 
Buffers Content Manufacturer 
Standard PCR buffer 500mM KCl 
100mM Tris, pH 8.3 
15mM MgCl2 
0.25% Tween 20 
2.5% BSA  
Merck 
Roth 
Fluka 
Sigma-Aldrich 
Sigma-Aldrich 
iProof HF buffer  Bio-Rad 
 
Southern blotting 
Product Manufacturer 
MinElute Gel Extraction Kit Qiagen 
Maxtract high density tubes Qiagen 
Restriction endonuclease KpnI New England Biolabs 
Restriction endonuclease Spe I New England Biolabs 
GeneRuler 1kb DNA Ladder Fermentas 
GeneRuler 1kb Plus DNA Ladder Fermentas 
Nylon membrane, positively-charged Roche 
Prime-a-Gene Labeling System Promega 
[α-32P]-dCTP, Specific Activity:  3000Ci/mmol (10mCi/ml) Perkin Elmer 
illustra MicroSpin S-400 HR Columns GE Healthcare 
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Buffers Content Manufacturer 
Depurination buffer 0.2N HCl AppliChem 
Denaturation buffer 0.5N NaOH 
1.5M NaCl 
AppliChem 
Sigma-Aldrich 
Neutralisation buffer 0.5M Tris, pH 7.5 
1.5M NaCl 
Roth 
Sigma-Aldrich 
Transfer buffer 20x SSC Sigma-Aldrich 
Hybridisation buffer 0.5M sodium phosphate 
1mM EDTA 
5% SDS  
100µg/ml salmon sperm DNA 
Merck 
Sigma 
AppliChem 
Invitrogen 
Washing buffer 1  2x SSC 
0.05% SDS 
Sigma-Aldrich 
AppliChem 
Washing buffer 2 0.1x SSC 
0.1% SDS 
Sigma-Aldrich 
AppliChem 
 
 
2.2 Methods 
2.2.1 SLC2A3 
SLC2A3 genotyping 
CNV: A TaqMan Copy Number Assay was performed to genotype the CNV 
comprising the SLC2A3 gene locus, based on a quantitative PCR (qPCR) reaction. 
The TaqMan assay ‘Hs 04406005_cn’ produces an amplicon of 98 bp length, located 
within intron 6 of SLC2A3 (Chr12: 8081061). While the ‘Hs 04406005_cn’ probe is 
labelled with a FAM-dye, the reference probe that targets the RNase P gene is VIC-
dye-labelled. This gene was selected for normalisation as it is known to always have 
two copies.  
The qPCR reaction mix contained 5µl TaqMan Universal PCR Mix, 3µl H2O, 0.5µl 
TaqMan ‘Hs 04406005_cn’ solution, 0.5µl TaqMan RNase P solution as well as 1µl 
DNA (10ng/µl). The reaction took place in a CFX 384 PCR cycler using the following 
programme:  
 
Step Temperature Number of cycles Duration 
Preheating 50°C 1 2min 
Activation of enzyme 95°C 1 10min 
Denaturation 
 
Annealing/Extension 
95°C 
 
60°C 
 
                     40 
 
15sec 
 
1min 
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During the programme, an automatic threshold in the logarithmic phase of the 
amplification was assessed and expression was indicated based upon cycle 
threshold (Ct) values. Data was analysed with the assistance of the CopyCaller 
software by assuming that the overall copy number of the samples is 2.  Samples 
were measured in triplicates and repeated if different from 2 or showing a range 
greater than 0.5.   
 
SNP: The SNP rs12842, located within the 3’UTR of the SLC2A3 gene (see Figure 
5), was investigated by the Sequenom iPlex method according to the manufacturer’s 
instructions. PCR was performed using iPlex chemistry as recommended in the 
MassArray iPlex standard operating procedure and using 40ng genomic DNA. The 
SNP was then genotyped by primer extension and analysed by matrix-assisted laser-
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). 
 
 
Fig. 5: Position of the SNP rs12842 within the SLC2A3 gene 
The location of eleven SNPs within and around the SLC2A3 gene locus is illustrated. The exons of SLC2A3 are represented by 
dark green rectangles and the SNP rs12842, located within the 3’UTR of SLC2A3, is highlighted in red [adapted and modified 
from www.ncbi.nlm.nih.gov/projects/SNP; hg19]. 
 
Confirmation of SLC2A3 CNV genotyping 
To confirm the results of the aforementioned TaqMan genotyping assay, 
Fluorescence In Situ Hybridisation (FISH) and Array Comparative Genomic 
Hybridisation (array CGH) was used. While the required cell lines and DNA samples 
were prepared at the Department of Psychiatry in Würzburg, the experiments 
themselves were conducted by Dr. Indrajit Nanda (Department of Human Genetics, 
University of Würzburg) and Dr. Reinhard Ullmann (MPI for Molecular Genetics, 
Berlin). 
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Fluorescence In Situ Hybridisation (FISH): lymphoblastoid cell lines were obtained 
from two individuals whose TaqMan results were suggestive of a SLC2A3 duplication 
(3 copies), and also from a control subject with 2 copies. Metaphase chromosomes 
of LCLs were prepared according to standard procedures and the BAC clone RP11-
277E18 was used, encompassing the region corresponding to the SLC2A3 gene. By 
means of nick translation, BAC DNA was directly labelled with Fluorescein-12-dUTP, 
followed by overnight hybridisation to denatured chromosomal DNA. After 
counterstaining with DAPI and mounting in Antifade medium, slides were examined 
with an epifluorescence microscope. 
Array Comparative Genomic Hybridisation (array CGH): Genomic DNA samples from 
twelve subjects with a TaqMan-assessed SLC2A3 copy number of 3 were used 
together with reference DNA samples (two copies). For array CGH, total genomic 
DNA was sonicated to a length of 0.1-2kb, purified with a PCR Purification Kit and 
subsequently labelled by means of a Random Prime Labeling System, using Cy3-
dUTP for sample DNA and Cy5-dUTP for reference DNA. After denaturation, labeled 
DNA samples were co-hybridised onto arrays of genomic BAC clones spotted on 
epoxy-coated slides, before finally high-stringency washed slides were analysed by 
means of an Axon 4000B scanner and the software Genepix. Fluorescence 
intensities of all spots were calculated after subtraction of local background and copy 
number variations were determined by conservative log2 ratio thresholds of 0.3 and -
0.3, respectively.  
 
Cell culture 
Peripheral blood samples were collected in EDTA tubes and subsequently subjected 
to Ficoll density gradient centrifugation to isolate mononuclear cells (such as 
monocytes and lymphocytes). Around one half of this fraction was used directly as 
native samples (peripheral blood mononuclear cells, PBMCs) with the other half 
undergoing an immortalisation procedure based on Epstein-Barr virus (EBV) 
infection. For this purpose, cells were incubated overnight in medium supplemented 
by sterile-filtered supernatant of B95.8 monkey epithelial cells infected with EBV. The  
resulting immortalised cells which derive from b-lymphocytes and are known as 
lymphoblastoid cell lines were propagated in lymphoblast culture medium for several 
weeks. 
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RNA extraction and quantitative reverse transcription (qRT) PCR 
PBS-washed PBMC or LCL pellets were stored in RNAprotect Cell Reagent at -20°C 
until RNA extraction was performed. Total RNA of cells was isolated according to 
manufacturer’s instructions by means of an RNeasy Plus Mini Kit. RNA concentration 
and purity were determined via a NanoDrop spectrometer, while RNA integrity was 
assessed based upon agarose gel electrophoresis and an automated electrophoresis 
system (Experion). For reverse transcription, a cDNA Synthesis Kit was used 
according to the supplier’s protocol, with 500ng of total RNA serving as template. The 
resulting cDNA containing solution was diluted in TE buffer (1:5) and stored at -20°C. 
 
The qRT-PCR took place in a C1000 Thermal Cycler whose wells contained a 
volume of 10µl each (5µl iQ Sybr Green Supermix, 3µl H2O, 1µl primer and 1µl cDNA 
solution). Samples were run in triplicates and underwent the following programme: 
 
Step Temperature Number of cycles Duration 
Initial denaturation 95°C 1 5min 
Denaturation 
 
Annealing/Extension 
95°C 
 
60°C 
 
                     40 
 
10sec 
 
30sec 
Melt curve 95°C for 10sec, then gradient from 65 to  95°C (temperature increment: 0.5°C per 0.05sec) 
 
 
In addition to self-designed primers specific to human SLC2A3 cDNA, Qiagen 
quantitect primers for human PGK1, ALAS1, B2M and GAPDH were used as loading 
controls. In order to determine mean PCR efficiency values for each primer, raw 
measuring data were processed by means of LinRegPCR software, and 
subsequently the relative SLC2A3 expression was normalised according to the most 
stable loading controls, with the assistance of the software geNorm. 
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Protein extraction and Western blotting 
PBS-washed PBMC or LCL pellets were sonicated in RIPA buffer supplemented by 
Protease inhibitors and resulting lysates were subjected to centrifugation at 10000g 
for 10min at 4°C. Protein concentration of supernat ants was assessed based upon a 
BCA assay using a microplate spectrophotometer. For LDS-based electrophoresis 
under reducing conditions, 10µg protein was loaded into each well of a 4-12% Bis-
Tris Gel and subsequently transferred onto a nitrocellulose membrane. After blocking 
in Tris-buffered saline with 0.1% Tween-20 (TBS-T) containing 5% non-fat dry milk, 
the membrane was incubated overnight with Rabbit Anti-GLUT3 antibody. The 
following day, membrane was incubated with a secondary antibody (anti-Rabbit 
labeled with horseradish peroxidase) and then with ECL detection system (ECL 
Prime). Furthermore, the membrane was placed into a ChemiDoc system in order to 
take a photo of the chemiluminescence signal. After the removal of antibodies from 
the membrane via stripping buffer and blocking in TBS-T containing 5% BSA, the 
membrane was incubated with a loading control antibody directed against beta-actin 
and detected as described above. Densitometric quantification of GLUT3 protein 
amounts was performed by means of the software AIDA, and GLUT3 intensities were 
divided by the respective ones of the loading control (beta-actin) for normalisation. 
 
 
Cellular glucose uptake assay 
To measure glucose uptake in LCLs, every cell sample was cultivated under 
standardised conditions 48h prior to the experiment. For this purpose, PBS-washed 
LCLs were transferred from their normal culture flasks into 24-well plates with each 
well containing 5x105 cells in 2ml lymphoblast culture medium.  
On the day of the uptake measurement, cells were counted again with a cellometer, 
washed with PBS and pelletted. Each sample (5x105 cells) was subsequently 
incubated for 20min at 37°C in 300µl glucose-free R PMI medium supplemented by 
1.5µl 3H-labelled deoxy-glucose. After centrifugation, cell pellets were washed with 
PBS and then lysed with 400µl 0.05N NaOH. Having added 4ml Rotiszint scintillation 
cocktail to every sample, radioactivity was measured via an LS6500 Multipurpose 
Scintillation Counter. Samples were run in pentaplicates along with ‘Cyt B control’ 
samples, incubated in the presence of cytochalasin B (100µM) in order to correct for 
non-specific glucose uptake. 
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Functional EEG measurements 
Performed by Dr. Ann-Christine Ehlis (Department of Psychiatry, University of 
Tübingen), participants in this study were subjected to a Continuous Performance 
Test (CPT) and an n-back test. During both tasks, event-related potentials (ERPs), 
i.e. the electrophysiological responses of the brain to a specific stimulus, were 
measured via Electroencephalography (EEG). 
 
CPT: This test is known as a neuropsychological task that helps to assess 
characteristics, such as selective attention and cognitive response control (Riccio et 
al., 2002; Fallgatter et al., 2012).   
In our case participants sat in front of a computer screen showing a pseudo-
randomised sequence set of 12 different letters with a stimulus presentation time of 
200ms and an interstimulus interval of 1650ms. Whenever the letter ‘O’ was directly 
followed by the letter ‘X’, participants had to press the space bar of a keyboard (Go- 
condition) with their right hand, whereas and otherwise had to suppress this reaction 
in case any letter other than ‘X’ appeared (NoGo condition). The CPT started 
following a short training session and took approximately 13min. Both accuracy and 
response speed were emphasised.  
An important CPT parameter is the so-called NoGo-Anteriorisation (NGA) that 
reflects the anteriorisation of the positive EEG field area (centroid) during the NoGo 
compared to the Go condition. Generally, NGA is considered a topographical ERP 
marker of cognitive response control, indicating prefrontal brain activity during motor 
inhibition (Fallgatter et al., 2002).  
For the calculation of the NGA values in the P300 time window (~300ms after the 
stimulus), the localisation of the NoGo centroid was subtracted from that of the Go 
centroid. Given that the measuring unit reflects the relative electrode position, an 
NGA value of 1.0 implies that the centroid is shifted precisely one electrode position 
in the anterior direction during a CPT NoGo trial. 
 
n-back test: This task resembles the aforementioned CPT, yet is designed as a 
measure of working memory (Cohen et al., 1997), with 9 different letters sequentially 
presented for this paradigm (using the same stimulus and interstimulus duration as 
described above). Participants had to press a response button whenever the current 
letter matched the one from n steps earlier in the sequence. In our case, both a 1-
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back and a 2-back condition were carried out, each comprising 216 trails, and only 
trials with a correct response were included. Key measures of the test were 
perceptual sensitivity (participant's ability to distinguish between targets and non-
targets) and response bias (participant's readiness to respond). 
 
For both the CPT and the n-back, EEG signals were recorded from 21 scalp 
electrodes placed according to the international 10-20 system, by means of a 32-
channel DC BrainAmp amplifier and the software Brain Vision Recorder. For the 
examination of eye movements (electrooculogram), three additional electrodes were 
placed around the eyes: two at the outer canthi of both eyes (reference for horizontal 
eye movements) and one below the right eye (reference for vertical eye movements). 
Ocular artifacts were corrected by means of an algorithm included in the Vision 
Analyzer software. 
 
Statistical Analysis 
Student’s t-test was used for gene expression analyses and cellular glucose uptake 
assay. However, if assumption of normal distribution could not be upheld, a Mann-
Whitney-U (MWU) test was conducted instead. 
 
For the EEG measurements, ANOVAs and Student’s t-tests for independent samples 
were applied to examine the potential influence of SLC2A3 duplication status and 
rs12842 genotype on EEG data. Student’s t-tests for independent or matched 
samples were used to conduct post-hoc analyses and check potential effects of 
SLC2A3 duplication status on reaction times, NGA values and Go/NoGo centroids. 
Furthermore, variables to which the assumption of normal distribution did not apply 
were confirmed using non-parametric testing. 
All p-values smaller than 0.05 were considered statistically significant, whereas p-
values between 0.1 and 0.05 were considered as a statistical trend. 
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2.2.2  Lphn3 
The knockout technique 
The principle of generating targeted and inheritable genetic mutations in mammals 
was developed in the 1980s, and has been primarily established for mice. If the 
introduced modification gives rise to a completely dysfunctional gene, it is referred to 
as being ‘knocked-out’ and the resulting mice are termed as ‘knockout mice’.  
Several steps are necessary in achieving this goal, commencing with a gene-specific 
DNA vector that is transfected into cultivated murine embryonic stem (ES) cells. 
Those ES cells that have correctly integrated the modified allele into their genome by 
replacing the respective wildtype allele (homologous recombination) are selected and 
injected into early mouse embryos (morula or blastula stage). If implanted into the 
uterus of surrogate mothers, these embryos have the potential to develop into so-
called chimeric mice, whose body cells derive both from injected and from host ES 
cells. After germline transmission of the modified allele, heterozygous offspring can 
be bred with each other in order to yield mice carrying the mutation homozygously. 
 
Design of Lphn3 targeting vector 
With regard to the murine Lphn3 gene, in silico analysis revealed that targeting its 6th 
exon should result in a reliable knockout allele, given that the excision of this 214bp 
DNA sequence produces a frameshift mutation and thus a premature stop codon in 
the 9th exon, giving rise to a truncated and likely non-functional protein. 
We decided to use the so-called recombineering technique (recombination-mediated 
genetic engineering) to generate a DNA vector that targets Lphn3 exon 6. This 
comparatively new method is based on insertion of DNA fragments into a plasmid 
backbone via homologous recombination which occurs in vivo, i.e. in certain E. coli 
strains, capable of expressing recombination genes of the bacteriophage λ 
(Copeland et al., 2001).  
A BAC clone (RP24-74E24) comprising parts of the murine Lphn3 genomic region 
was ordered at the BACPAC Resources Center (Oakland, USA) and electroporated 
into DY380 E. coli cells (Liu et al., 2003). On the other hand, short homologous 
sequences, corresponding with parts of the Lphn3 exon 6 region, were added to the 
high-copy plasmid PL253 (kindly provided by Dr. Tobias Langenhan, Department of 
Physiology, University of Würzburg) via an anchor primer-based PCR reaction. This 
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linear PCR product was subsequently electroporated into the aforementioned BAC-
containing DY380 bacteria which were supposed to facilitate the subcloning of the 
Lphn3 exon 6 region into the high-copy plasmid (‘gap-repair’) based upon 
homologous recombination (see Figure 6). However, for unknown reasons, this 
recombination process did not work out in our case, despite the experiment being 
performed several times with all components double-checked (for example via DNA 
sequencing of the BAC). Fortunately, in the meantime a final Lphn3 targeting vector 
was produced and offered by the Helmholtz Center in Munich.  
 
 
Fig. 6: Subcloning of a DNA sequence from a BAC into a high-copy plasmid via recombineering 
Using an anchor primer-based PCR reaction, short homologous sequences (violet and blue rectangles) can be added to a high-
copy plasmid backbone (pSK+). Subsequently, this PCR product is transformed into recombination-competent bacteria which 
already contain a particular BAC (exhibiting the above-mentioned homologous sequences as well). Within these cells, 
recombineering results in a gap-repaired plasmid that can be selected via its ampicillin (amp) resistance [adapted and modified 
from Liu et al., 2003]. 
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Like the one we were planning, this vector targets the 6th exon of Lphn3 and exhibits 
all features necessary for the generation of knockout mice, thus prompting our 
decision to use it. As can be seen in Figure 7, the vector contains a high-copy 
pD223-based backbone, including a diphtheria toxin A (DTA) cassette for negative 
selection of ES cells. Furthermore, the backbone comprises a spectinomycin 
resistance cassette (SpecR) for positive selection of bacteria as well as a single AsiSI 
restriction site that can be used for linearisation.  
 
 
Fig. 7: Illustration of the final Lphn3 targeting vector (provided by the Helmholtz Center, Munich) 
Among others, the vector contains the exon 6 of Lphn3 (ENSMUSE00000335450; current name: ENSMUSE00001133342) and 
the anterior parts of its flanking introns (5’ arm and 3’ arm). Moreover, a lacZ trapping cassette and a neomycin resistance 
cassette (neo) can be found. Importantly, exon 6 is surrounded by loxP sites, whereas the lacZ and neo cassettes are 
surrounded by FRT sites [adapted from www.knockoutmouse.org/martsearch/project/40290]. 
 
The gene-specific part of the vector consists of Lphn3 exon 6 
(ENSMUSE00000335450; current name: ENSMUSE00001133342) and the anterior 
parts of its flanking introns (5’ arm and 3’ arm). These two arms allow the 
replacement of the respective wildtype allele in ES cells via homologous 
recombination. Importantly, exon 6 is surrounded by loxP sites in the vector 
construct. These short DNA sequences are known as recognition sites for the viral 
enzyme Cre recombinase. If two loxP sites are equally oriented on the same DNA 
strand, the sequence between these sites is termed as ‘floxed’ (flx) and can be 
excised by Cre. If the Cre gene is placed under the control of an appropriate 
promoter, its expression can be tightly regulated, allowing to delete the floxed 
sequence in a tissue- or time-specific manner (conditional knockout principle). 
Between the 5’ arm and the floxed exon 6, the vector contains a lacZ trapping 
cassette and a neomycin resistance cassette (neo). While the first can be used to 
simultaneously disrupt and report Lphn3 gene function in mice (knockout-first 
principle), the latter serves as a positive selectable marker when growing ES cells in 
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the presence of geneticin (G418). Both cassettes are flanked by so-called FRT sites, 
which function analogously to the aforementioned Cre-loxP recombination system, 
albeit depending on the enzyme Flp recombinase.  
 
Amplification and linearisation of Lphn3 targeting vector 
The targeting vector was transformed into TOP10F´ E.coli bacteria, amplified and 
purified by means of a Maxiprep Kit following the manufacturer’s instructions. Using 
the restriction endonuclease AsiSI, the vector was linearised and subsequently 
rinsed with ethanol. Finally, the precipitated vector was resuspended in PBS and 
stored at -70°C.  
 
Murine embryonic stem (ES) cell culture 
ES cells were grown on mitomycin C-inactivated SNL feeder cells in gelatinised Petri 
dishes. ES cell medium was changed every 24h and ES cells were passaged every 
48h, i.e. SNL cells were replaced. For electroporation, ES cells were trypsinised and 
separated from the SNL layer. After dissociation, 6x106 ES cells were washed in 
PBS, resuspended in Nucleofector solution and electroporated with 3.5µg linearised 
Lphn3 targeting vector. Cells were grown under normal conditions during the first 48h 
after electroporation and subsequently in the presence of 150µg/ml G418. After 
several days, ES cell colonies that had survived the selection process were selected 
and propagated in G418-containing medium. 
 
PCR 
Short-range PCR: To prove the presence of three critical sequences in the ES cell 
genome (5’ FRT site, 3’ FRT site as well as 3’ loxP site; see Fig. 7), short-range PCR 
was performed, resulting in amplicons of 224bp, 544bp and 413bp, respectively. For 
this purpose, PBS-washed cell pellets were lysed in Cell lysis buffer and DNA was 
purified by isopropanol precipitation. The short-range PCR reaction mix contained 
18.2µl H2O, 2.5µl Standard PCR buffer, 1µl dNTPs, 1µl forward primer, 1µl reverse 
primer, 1µl template DNA (genomic DNA: 25ng; vector DNA: 0.1g) and 0.3µl Taq 
DNA polymerase. All samples underwent the following programme: 
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Step Temperature Number of cycles Duration 
Initial denaturation 95°C 1 120sec 
Denaturation 
Annealing 
Extension 
95°C 
60°C 
72°C 
 
                    30 
 
30sec 
30sec 
90sec 
Final extension 72°C 1 120sec 
 
 
Long-range PCR: Samples that showed correct amplicons in all three short-range 
PCR reactions were further checked by means of a single long-range PCR reaction, 
with the corresponding amplicon having a size of 4807bp and spanning the whole 5’ 
arm of the vector construct. The target sequence of the forward primer was located in 
the Lphn3 intronic region upstream of the 5’ homology arm (i.e. not present in the 
vector construct), while the reverse primer was bound to a construct-specific 
sequence near the 5’ FRT site (see Figure 8). Accordingly, this PCR reaction was 
able to verify the site-directed integration of the vector construct into the ES cell 
genome at the 5’ homology arm. The long-range PCR reaction mix contained 14.75µl 
H2O, 5µl iProof HF buffer, 2µl dNTPs, 1µl forward primer, 1µl reverse primer, 1µl 
template DNA (25ng) and 0.25µl iProof DNA polymerase. Samples underwent a 
Touchdown PCR programme, implicating that annealing temperature started at 70°C 
and was reduced by 0.5°C every cycle down to a ‘tou chdown’ point of 60°C: 
 
Step Temperature Number of cycles Duration 
Initial denaturation 98°C 1 120sec 
Denaturation 
Annealing 
Extension 
98°C 
Touchdown 
72°C 
 
                    32 
 
10sec 
20sec 
150sec 
Final extension 72°C 1 300sec 
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Fig. 8: Comparison of the Lphn3 exon 6 wildtype allele with the Lphn3.flx/frt allele 
The expected Lphn3.flx/flrt allele originates from homologous recombination between the Lphn3 targeting vector and the 
corresponding genomic region of Lphn3. PCR primers are illustrated by small arrows (dark blue: 5’ long-range PCR, orange: 5’ 
FRT short-range PCR, light blue: 3’ FRT short-range PCR, pink: 3’ loxP short-range PCR, green: southern probe PCR). Dashed 
vertical lines represent restriction recognition sites for the endonucleases SpeI or KpnI.  
 
 
Southern blotting 
To prove the site-directed integration of the vector construct into the ES cell genome 
at the 3’ homology arm, Southern blotting experiments were performed.  
A 965bp DNA probe that targeted the Lphn3 genomic region immediately 
downstream to the 3’ homology arm (see Figure 8) was PCR-amplified following a 
protocol analogous to that described above (short-range PCR protocol), before the 
probe was subsequently gel-purified by means of a Gel Extraction Kit. The same 
protocol as for PCR was used for ES cell DNA extraction and purification, albeit with 
a phenol-chloroform extraction step by means of Maxtract tubes. 10-15µg DNA per 
sample were double-digested with the restriction endonucleases SpeI as well as 
KpnI, and subsequently subjected to a 0.8% TAE-buffered agarose gel. The 
restriction fragment which was later detected by the aforementioned probe, had a 
size of 9586bp in wildtype DNA, while homologous recombination with the Lphn3 
targeting vector was predicted to lead to an additional restriction site (KpnI) and thus 
a shorter fragment size (7962bp) in heterozygous Lphn3.flx/frt ES cells (see Figure 
8). After electrophoresis, the gel was incubated successively in three different buffers 
(depurination, denaturation and neutralisation) followed by capillary transfer of DNA 
bands to a nylon membrane. The membrane was subsequently dried at 80°C, and 
DNA bands were crosslinked using UV light.  
According to the supplier’s instructions, the probe was labelled with 32P by means of 
a DNA Labeling Kit, and non-incorporated α-32P-dCTPs were removed via MicroSpin 
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Columns. Prehybridisation of the membrane was carried out in hybridisation buffer at 
65°C for 1h, with this buffer subsequently replaced  by a fresh hybridisation buffer 
supplemented with denatured radioactive probe (20µl/ml). Following overnight 
hybridisation at 65°C, the membrane was rinsed seve ral times in washing buffer 1 
and 2 with increasing temperature, and then placed onto an autoradiography film 
developed the next day with the help of conventional photo laboratory equipment.  
 
Additional quality checks 
DNA sequencing: To verify the integrity of FRT and loxP sites in the genome of ES 
cell clones that had passed all preceding quality checks, amplicons of the 
aforementioned short-range PCRs were gel-purified via a Gel Extraction Kit and 
subsequently forwarded to the company Eurofins MWG Operon for DNA sequencing.  
Mycoplasma test: To check for the potential infection of ES cells with Mycoplasma 
bacteria, a subset of cells was cultivated separately for several days without the 
presence of any antibiotics, and the medium was examined for Mycoplasma-specific 
DNA sequences using a Mycoplasma PCR Detection Kit according to the supplier’s 
descriptions. This kit includes two control samples: a negative control which 
produces a PCR product of 481bp and a positive control, giving rise to both a 481bp 
and a 259bp amplicon. 
 
Karyotyping: Moreover, ES cell chromosomes were prepared and stained with DAPI 
to obtain respective karyograms, with at least 15 different cells in metaphase 
analyzed for each clone. All karyotyping experiments were kindly performed by Dr. 
Indrajit Nanda (Department of Human Genetics, University of Würzburg).  
 
Morula injection 
For the production of embryos, female mice were superovulated with intraperitoneal 
injections of pregnant mare serum gonadotrophin (PMSG) and human chorionic 
gonadotrophin (hCG). Chimeric Lphn3.flx/frt mice were generated by laser-assisted 
injection of successfully recombined ES cells (JM8A3 cell line; carrying the agouti 
coat colour gene) into 8-cell stage embryos (morulae) deriving from mice with black 
coat colour (C57BL/6), while pseudopregnant female mice produced via mating with 
vasectomised males were used as recipients for injected embryo transfer. All 
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manipulations were performed by Ronald Naumann and his colleagues (MPI-CBG, 
Dresden).  
 
Mice breeding and genotyping 
Mice were kept under controlled humidity (44-48%) and temperature (22-23°C) 
conditions with a regular 14/10 hour light-dark cycle. Drinking and feeding were ad 
libitum. 
 
Chimeras were crossed to C57BL/6 mice and screened by PCR for germline 
transmission. This duplex PCR was capable of producing amplicons of varying sizes, 
given that every reaction mix contained one forward primer and two reverse primers 
(one of which was vector construct-specific). While the Lphn3 wildtype allele 
corresponded to a PCR product of 446bp, the Lphn3.flx/frt allele produced a 224bp 
amplicon (and theoretically an additional amplicon of 7540bp). DNA from mouse tail 
tips was used as PCR template, extracted analogously to the ES cell DNA (see 
above). 
  
The PCR reaction mix contained 18µl H2O, 2.5µl Standard PCR buffer, 1µl dNTPs, 
1µl forward primer (5’ FRT site forward), 0.5µl reverse primer #1 (5’ FRT site 
reverse), 0.5µl reverse primer #2 (3’ FRT site reverse), 1µl template DNA (25ng) and 
0.5µl Taq DNA polymerase. Samples underwent a Touchdown PCR programme, 
implying that annealing temperature started at 66°C  and was reduced by 0.5°C every 
cycle down to a ‘touchdown’ point of 56°C: 
 
Step Temperature Number of cycles Duration 
Initial denaturation 95°C 1 120sec 
Denaturation 
Annealing 
Extension 
95°C 
Touchdown 
72°C 
 
                    35 
 
30sec 
30sec 
90sec 
Final extension 72°C 1 120sec 
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3 Results 
3.1 SLC2A3 
3.1.1 Confirmation of SLC2A3 CNV genotyping 
Two additional methods were performed in order to verify the specificity of the 
SLC2A3 TaqMan CNV assay. 
 
Fluorescence In Situ Hybridisation (FISH) 
Metaphase chromosomes of all three analysed subjects exhibited the fluorescence 
hybridisation signals at the expected site of chromosome 12 (p13.31). However, the 
signal intensity on one of the homologous chromosomes was significantly brighter in 
both SLC2A3 duplication carriers, and covered a larger region (see Figure 9). The 
hybridised region emerged as two distinct blocks during some metaphase stages, 
which implies the presence of additional copies of the BAC probe. Furthermore, 
when the same BAC was hybridised on metaphase chromosomes of the control 
subject (who had 2 SLC2A3 copies according to the TaqMan assay) or when other 
BACs covering the short arm of chromosome 12 were used, the presence of 
additional copies of the probe could not be revealed (data not shown).  
 
Fig. 9: SLC2A3 Fluorescence In Situ Hybridisation (FISH) on human chromosomes 
For hybridisation, the BAC RP11-277E18 comprising the SLC2A3 gene locus on chromosome 12 (p13.31) was used. The 
image shows two labelled homologous chromosomes of an individual that was a carrier of three SLC2A3 copies according to 
TaqMan-based genotyping. Importantly, one of the homologs (left) displayed a considerably brighter and larger signal implying 
additional copies of the BAC probe [by courtesy of Dr. Indrajit Nanda, Department of Human Genetics, University of Würzburg]. 
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Array Comparative Genomic Hybridisation (array CGH) 
DNA samples of twelve human individuals were examined, with each showing 
evidence of three SLC2A3 copies in preceding TaqMan assays. In all cases, a 
duplication comprising the SLC2A3 gene locus could be confirmed. Moreover, this 
duplication was consistently found to have a minimal size of 127482bp 
(chr12:7996763-8124244, hg19) and a maximal size of 132017bp (chr12:7993703-
8125719; see Figure 10). Given that both chromosomal breakpoints were located in 
segmental duplications showing a high degree of sequence similarity (first duplicon at 
chr12:7995630-7998390, second duplicon at chr12:8124315-8128199; fraction 
matching: 0.9214), non-allelic homologous recombination (NAHR) appears to be the 
duplication’s most likely cause. 
 
 
Fig. 10: Illustration of array CGH data for chromosome12: 7166455-8822108 (hg19) 
This representative image shows the findings for a human individual whose TaqMan results were indicative of three SLC2A3 
copies. Signal intensity ratios of Cy3 and Cy5 are displayed for each BAC clone. The red line corresponds to a log2 ratio of -0.3 
(loss), whereas the green line represents a log2 ratio of 0.3 (gain). The duplication comprising the SLC2A3 gene locus was 
found to have a minimal size of 127482bp and a maximal size of 132017bp [Image kindly provided by Dr. Reinhard Ullmann, 
MPI for Molecular Genetics, Berlin]. 
 
 
 
 
 
Maximal size: 132017bp  
(chr12:7993703-8125719) 
Minimal size: 127482bp  
(chr12:7996763-8124244) 
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3.1.2 Quantitative reverse transcription (qRT) PCR 
Real-time qRT-PCR was performed to analyse the expression of SLC2A3 in two 
easily available peripheral human cell models. The SLC2A3 comprising CNV exerted 
a strong influence on SLC2A3 mRNA levels in both native (PBMCs) and immortalised 
cells (LCLs). As shown in Figure 11,  mean normalised relative expression values 
(mean Qn) were significantly higher in the group of duplication carriers (copy number: 
3) than the group of controls (copy number: 2). This difference was 73.1% in terms of 
LCLs (MWU test, p<0.01), while it amounted to 220% in PBMCs (MWU test, 
p<0.001). 
 
 
 
Fig. 11: Real-time qRT-PCR for SLC2A3  
The histograms display mean normalised relative expression values (mean Qn ± SEM in arbitrary units) for carriers of the 
SLC2A3 duplication (CN3) and control individuals (CN2). Figure a corresponds to peripheral blood mononuclear cell (PBMC) 
samples and figure b to lymphoblastoid cell line (LCL) samples [Mann-Whitney U test:  ** p<0.01, *** p<0.001, n: sample size]. 
 
 
3.1.3 Western blotting 
SLC2A3 expression analysis at the protein level was conducted using the 
aforementioned peripheral cell models. For this purpose, densitometrically 
determined relative GLUT3 protein levels were compared between carriers of the 
SLC2A3 duplication (3 gene copies) and control subjects (2 gene copies). However, 
no significant impact of the SLC2A3 CNV on whole cell GLUT3 protein quantity could 
be found. As seen in Figure 12, which refers to Western blotting experiments in 
native cells (PBMCs), duplication carriers exhibited nominally increased (37%) 
GLUT3 protein amounts in comparison to controls, albeit without reaching the level of 
significance (t-test, p=0.265). In immortalised cells (LCLs), GLUT3 protein levels 
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proved to be non-significantly diminished by 21% in duplication carriers (t-test, 
p=0.219; data not shown). 
 
 
Fig. 12: Western blotting for GLUT3 
Figure a shows the image of a representative immunoblot, reflecting whole cell GLUT3 protein amounts of SLC2A3 duplication 
carriers (‘D”) and control subjects (‘C”) in peripheral blood mononuclear cells (PBMCs). GLUT3 levels were normalised by 
means of the loading control protein beta-actin (Figure b). The histogram in Figure c displays the relative GLUT3 protein 
expression in PBMCs (± SEM in arbitrary units) which was non-significantly higher (37%; p=0.219) in SLC2A3 duplication 
carriers (CN3) than individuals with two gene copies (CN2) [Mann-Whitney U test, n: sample size]. 
 
 
3.1.4 Cellular glucose uptake assay 
LCLs were incubated in the presence of 3H-labelled 2-Deoxy-D-glucose for the 
analysis of GLUT-mediated glucose uptake. As displayed in Figure 13, no significant 
differences in cellular glucose uptake were found between duplication carriers (3 
SLC2A3 copies) and control individuals with 2 copies. Mean scintillation recordings 
amounted to 36375±5440 counts per minute (cpm) in the duplication, and 
38494±7629 cpm in the control group (MWU test, p=0.894). 
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Fig. 13: GLUT-mediated glucose uptake in lymphoblastoid cell lines (LCLs) 
3H-labelled 2-Deoxy-D-glucose uptake (counts per minute ± SEM) is displayed for human carriers of the SLC2A3 duplication 
(CN3) and control subjects with two copies (CN2). Group differences were not significant [Mann-Whitney U test, p=0.894, n: 
sample size]. 
 
3.1.5 Functional EEG measurements 
In order to investigate the functional impact of SLC2A3 SNP and CNV in humans, 
functional EEG measurements were conducted while participants underwent a 
Continuous Performance Test (CPT) and an n-back test. 
 
CPT 
It emerged that ADHD patients with a duplication of SLC2A3 (3 copies) showed a 
significantly diminished NoGo-Anteriorisation (NGA; 0.31±0.57 electrode positions) 
compared to ADHD patients with a SLC2A3 copy number of 2 (0.85±0.37 electrode 
positions; t16=2.36, p=0.031, see Figure 14). Indeed, this effect was due to the 
centroid of the Go condition, which appeared significantly more anterior (3.33±0.52 
vs. 3.91±0.25 electrode positions; t12=3.008, p=0.011), whereas the NoGo 
topography did not reveal significant differences between these two groups 
(t16=0.302, p=0.767). Additionally, SLC2A3 duplication carriers with ADHD showed a 
statistical trend towards increased reaction times to Go stimuli (606.6±189.8ms) 
compared to ADHD patients with 2 SLC2A3 gene copies (483.70 ± 72.0ms; t10=1.82, 
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p<0.1). However, no group differences could be found concerning NoGo-related 
behavioural indices such as commission errors.   
 
 
Fig. 14: NoGo-Anteriorisation (NGA) values for participants with different SLC2A3 copy number 
The histogram shows NGA values during Continuous Performance Test (CPT) for ADHD patients and healthy controls, carrying 
either two or three SLC2A3 gene copies. NGA was significantly reduced in ADHD patients with three copies (CN3) when 
compared to ADHD patients with a copy number of 2 (CN2) [n: sample size, error bar: SEM, * p<0.05; by courtesy of Dr. Ann-
Christine Ehlis, Department of Psychiatry, University of Tübingen]. 
 
Overall, ADHD patients in this study did not significantly differ from healthy controls, 
despite the ADHD subgroup with 3 SLC2A3 copies displaying a tendency towards 
diminished NGA values compared to the healthy subgroup with 3 copies (t12=2.03, 
p=0.07). Furthermore, no significant genotype effect appeared when considering the 
whole control group (t8=0.67, p=0.52). 
 
Concerning the SNP rs12842 within the SLC2A3 gene (see Figure 5), a significant 
interaction between both factors (F1,211=4.16, p<0.05) emerged when performing an 
ANOVA including the between-subject variables ‘genotype’ (T-allele vs. C-allele 
carriers) and ‘diagnosis’ (ADHD vs. healthy controls; see Figure 15). Using a post-
hoc t-test, it was possible to pinpoint that T-allele carriers within the ADHD group 
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showed slightly increased NGA values compared to ADHD patients with rs12842 C-
allele (t142=1.91, p=0.058). By contrast, this genotype effect was reversed in healthy 
controls, albeit without reaching the level of significance. Additionally, the ADHD 
group displayed a significant reduction of NGA values compared to the controls, yet 
only in terms of the subgroup with C-allele (t161=2.99, p=0.003) 
 
 
 
Fig. 15: NoGo-Anteriorisation (NGA) values for participants with different rs12842 allele 
NGA values during Continuous Performance Test (CPT) are displayed for ADHD patients and healthy controls, carrying either 
rs12842 C- or T-allele. A significantly reduced NGA was found in ADHD patients with the C-allele when compared to ADHD 
patients with the same gene variant. Moreover, a tendency towards increased NGA values in T-allele carriers emerged within 
the ADHD group [n: sample size, error bar: SEM, ** p<0.01, # p<0.1; data kindly provided by Dr. Ann-Christine Ehlis, 
Department of Psychiatry, University of Tübingen]. 
 
n-back test 
Using ANOVA for repeated measurements of the amplitude of the P300 time window, 
a significant main effect of genotype (2 vs. 3 SLC2A3 copies) was found within the 
group of ADHD patients (F1,16=11.91, p=0.003), implying lower overall values in 
subjects with three gene copies. Moreover, significant interactions between ‘SLC2A3 
copy number’ and ‘condition’ (1-back vs. 2-back; F1,16=5.74, p=0.029), as well as ‘trial 
type’ (target vs. non-target; F1, 16=4.70, p=0.046), indicated that this effect was 
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particularly pronounced in 1-back trials (t16=3.94, p=0.001) and target trials (t14=3.44, 
p=0.004; see Figure 16). Additionally, a decrease in P300 amplitudes from 1-back to 
2-back blocks as well as target to non-target trials only emerged within ADHD non-
duplication group (t8=5.38, p=0.01 and t8=3.08, p=0.015). 
On the other hand, SLC2A3 copy number neither exerted a significant influence on 
P300 amplitudes in the group of healthy controls (p≥0.1), nor did it affect P300 
latencies in either of the two diagnosis groups (all F-values < 1.5, p>0.25). 
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Fig. 16: Electroencephalogram (EEG) during n-back test (1-back condition, target trials) 
For a time window of 1000ms, mean amplitudes [µV] of ADHD patients with different SLC2A3 copy number are depicted at 
electrode position PZ (midline parietal). Across a notable time span and particularly involving the P300 component, the SLC2A3 
duplication group (CN3) showed significantly diminished amplitudes compared to control subjects with two copies (CN2) 
 [** p<0.01; by courtesy of Dr. Ann-Christine Ehlis, Department of Psychiatry, University of Tübingen]. 
 
Regarding the SNP rs12842, genotype status had no significant impact on the P300 
component. However, ANOVA showed a statistical trend (F1,173=2.87, p<0.1) towards 
a main effect ‘genotype’ for another ERP component, namely N200. Interestingly, this 
effect was highly dependent on the n-back trial type (target vs. non-target), given that 
both factors significantly interacted with each other (F1,173=8.37, p=0.004). 
Furthermore, by means of post-hoc analysis, C-allele carriers in both diagnostic 
groups exhibited a significant increase in N200 latencies in non-target trials 
(214.2±19.3ms) compared to target trials (199.7±24.2ms; t134=8.13, p<0.001; 
Wilcoxon-Z=8.0, p<0.001), whereas such an effect was not evident in T-allele 
carriers (t41=1.15, Z=1.90, n.s.; see Figure 17). 
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Fig. 17: N200 latencies during n-back-test 
N200 latencies are shown for ADHD patients with rs12842 C- or T-allele during different n-back test conditions (1-back vs. 2-
back) and trial types (target vs. non-target stimuli). Highly significant effects were found in C-allele carriers concerning trial type, 
test condition and genotype [n: sample size, error bar: SEM, *** p<0.001, ** p<0.01; data kindly provided by Dr. Ann-Christine 
Ehlis, Department of Psychiatry, University of Tübingen]. 
 
3.2 Lphn3 
3.2.1 Confirmation of homologous recombination in murine ES cells 
Following several repeated electroporation experiments using the Lphn3 targeting 
vector, a total of 133 ES cell clones were chosen; 46 of which survived the 
subsequent selection with the antibiotic G418 and appeared morphologically normal 
(undifferentiated) throughout the propagation. The DNA of these clones was checked 
for vector-specific sequences and targeted homologous recombination by means of 
PCR and Southern blotting. 
 
PCR 
Short-range PCR: As illustrated by Figure 18, the expected short-range PCR 
amplicons only appeared in around half of the tested ES cell clones. Overall, 25 ES 
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cell clones were positive for all three short-range PCR experiments (5’ FRT, 3’ FRT 
and 3’ loxP PCR). 
 
 
Fig. 18: Short-range PCRs for the detection of Lphn3 vector-specific sequences 
Figure a refers to the 5’ FRT PCR (expected amplicon: 224bp), Figure b to the 3’ FRT PCR (expected amplicon: 544bp) and 
Figure c to the 3’ loxP PCR (expected amplicon: 413bp). About half of the ES cell samples were positive for all three PCR 
reactions [Lane 1: DNA size marker (‘GeneRuler 100bp Plus’), Lane 2: negative control (wildtype ES cell clone), Lane 3: 
positive control (Lphn3 targeting vector), Lanes 4-7: transfected ES cell clones]. 
 
Long-range PCR: These 25 clones were further tested for correct homologous 
recombination at the 5’ arm with long-range PCR (see Figure 19), with a total of 10 
different ES cell clones exhibiting the expected PCR amplicon of 4807bp. 
 
 
Fig. 19: Long-range PCR for 5’ homology arm (Lphn3) 
The image shows an exemplary photo of electrophoretically separated 5’ long-range PCR products. Some ES cell clones 
exhibited the predicted amplicon of 4807bp [Lane 1: DNA size marker (‘GeneRuler 1kb’), Lane 2: negative control (wildtype ES 
cell clone), Lanes 3-9: transfected ES cell clones]. 
 
Southern blotting 
As an additional confirmation of homologous recombination, albeit with regard to the 
3’ homology arm, the DNA of the ten ES cell clones that passed all PCR experiments 
was checked by means of Southern blotting (see Figure 20). In addition to the 
9586bp Lphn3 wildtype fragment, all but two clones showed the expected 7962bp 
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fragment, indicating correct homologous recombination between the Lphn3 targeting 
vector and the corresponding sequences within the Lphn3 genomic region. 
 
 
Fig. 20: Southern blotting for 3’ homology arm (Lphn3) 
The autoradiography image shows DNA fragments detected by the 3’ southern probe. Besides the omnipresent 9586bp Lphn3 
wildtype fragment, several ES cell clones also exhibited the 7962bp fragment that indicated targeted integration of the Lphn3 
vector at the 3’ arm. Samples with ambiguous results (Lanes 3 & 4) were repeated [Lane 1: DNA size marker (‘GeneRuler 1kb 
Plus’), Lane 2: wildtype ES cell clone, Lanes 3-8: transfected ES cell clones, Lane 9: wildtype ES cell clone. Lane 10: DNA size 
marker (‘GeneRuler 1kb’)]. 
 
3.2.2 Additional quality checks for recombined ES cells 
The eight ES cell clones that emerged positive from all previous tests were further 
checked by means of the following three approaches: 
 
DNA sequencing 
To ensure the correctness of some particularly important sequences within the 
Lphn3.flx/frt allele, the aforementioned short-range PCR amplicons (5’ FRT, 3’ FRT 
and 3’ loxP PCR) were purified and subjected to DNA sequencing. In all cases, all 
three PCR products fully complied with the predicted sequence (data not shown).  
 
Mycoplasma test 
ES cells checked for potential infection by means of a PCR-based Mycoplasma test 
only gave rise to the 481bp negative control amplicon, yet not the 259bp positive 
control amplicon (see Figure 21). 
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Fig. 21: Mycoplasma test PCR for murine ES cell clones 
Mycoplasma PCR products are shown for 6 of the 8 tested ES cell clones. All clones exhibited only the negative control 
amplicon of 481bp, yet not an additional 259bp positive control band which indicates Mycoplasma infection of cells [Lane 1: 
DNA size marker, Lane 2-7: transfected ES cell clones, Lane 8: negative control, Lane 9: positive control]. 
 
Karyotyping 
Murine ES cells were karyotyped to check for gross structural and numerical 
rearrangements of chromosomes. Overall, seven ES cell clones showed the 
expected number of 40 acrocentric chromosomes, which appeared macrostructurally 
normal in all analysed metaphases. One ES cell clone was rejected, given that it 
repeatedly gave rise to karyograms with a diploid chromosomal number of 41 (see 
Figure 22). 
 
 
 
 
 
 
 
 
 
 
Fig. 22: Karyotyping of murine ES cell clones 
Two exemplary karyograms are shown, both comprising DAPI-stained chromosomes in random order. Whereas the ES cell 
clone in Figure a exhibited the expected number of 40 metaphase chromosomes per cell, the clone in Figure b repeatedly 
produced karyograms with 41 chromosomes [Image kindly provided by Dr. Indrajit Nanda, Department of Human Genetics, 
University of Würzburg]. 
 
 
40 
b a 
40 41 
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3.2.3 Generation of chimeric mice 
Among the seven ES cell clones that passed all preceding quality checks, four were 
chosen for morula injection; one of them led to offspring with a poor rate of chimerism 
(estimated on the basis of ES cell contribution to coat colour), whereas the others 
gave rise to highly chimeric mice whose body fur appeared almost entirely in agouti 
colour and that did not exhibit any pathological findings. These promising chimeras 
were raised and crossed with C57BL/6 mice. Animals of the next generation were 
carefully screened for germline transmission of the Lphn3.flx/frt allele on the basis of 
their coat colour and PCR genotyping (see Figure 23). However up to now, all mice 
of this generation (>100 animals) were found to be black-coated and homozygously 
wildtype in terms of the Lphn3 gene. Thus, the project is still in progress. 
 
 
Fig. 23: Lphn3 genotyping PCR for mice 
Depending on Lphn3 genotype, this duplex PCR was able to yield products of varying sizes: an amplicon of 446bp 
corresponded to the Lphn3 wildtype allele, whereas the Lphn3.flx/frt allele produced a 224bp amplicon. All mice tested thus far 
only displayed the wildtype band [Lane 1: DNA size marker, Lane 2: negative control (H2O), Lane 3: positive control 
(recombined ES cell clone), Lanes 4-9: offspring of chimeric mice]. 
 
 
 
 
                                                                                                                      Discussion 
___________________________________________________________________________________________________________________________________________________________________                                                 
54 
 
4 Discussion 
Several genome-wide screenings for ADHD have recently been conducted in a 
multitude of populations worldwide, suggesting a number of genes that may play a 
role in this highly prevalent neurodevelopmental disorder. In this context, two 
relatively new ADHD candidate genes have emerged: SLC2A3 which is known as the 
gene of the facilitative glucose transporter type 3, as well as LPHN3, encoding the 
protein latrophilin-3. 
 
Within this thesis, both genes were examined based upon two independent projects. 
In the first case, the focus was adopted on polymorphisms of SLC2A3 and their 
physiological consequences in humans, whereas the latter project involved 
developing a mouse model of latrophilin-3 deficiency. 
 
4.1 SLC2A3 
4.1.1 Confirmation of SLC2A3 CNV genotyping 
The reliability of the TaqMan Gene Expression Assay, routinely applied for SLC2A3 
CNV genotyping, could be confirmed in all cases by using two additional methods, 
namely Array Comparative Genomic Hybridisation (array CGH) and Fluorescence In 
Situ Hybridisation (FISH). Moreover, the extent of the duplication at the chromosomal 
location 12p13.31 was narrowed down to a maximal size of 132.017kb 
(chr12:7993703-8125719; hg19), which complies relatively well with the findings 
described in previous publications. For example, Yang and colleagues referred to a 
132.4kb duplication at chr12:7884583-8017012 (hg18; Yang et al., 2009), whereas 
Izumi and colleagues described a 128.8kb duplication at chr12:7888157–8017012 
(hg18; Izumi et al., 2012).  
 
When analysing the genomic region flanking the duplication, we found segmental 
duplications around the chromosomal breakpoints that exhibited a substantial level of 
sequence similarity (>92%), thus indicating a likely cause of non-allelic homologous 
recombination (NAHR) which is known to occur when low-copy repeats in the 
genome misalign during meiosis, leading to a gain or loss of genetic material. 
Interestingly, a Doctoral Thesis at the University of Leicester, United Kingdom, 
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focusing on the same CNV at 12p13.31 also considered NAHR the best explanation 
model (Reekie, 2011). However, the author surprisingly provided evidence of two 
distinct historical recombination events apparently having taken place at 12p13.31, 
resulting in two considerably different duplication alleles. The first, termed ‘B9/B10’, 
involves a duplication of the whole SLC2A3 gene locus and the anterior exons of 
SLC2A14, whereas the other duplication allele, termed ‘B5/B6’, implicates a 
SLC2A3-SLC2A14 fusion gene that may give rise to the synthesis of hybrid mRNA. 
However, according to Reekie and her colleagues, to date the B5/B6 recombination 
event has merely been verified in two related individuals of a West African population 
sample, and thus may possibly be restricted to this geographical region. Moreover, 
this allele is unlikely to be detected as a copy number change by the SLC2A3 
TaqMan Copy Number Assay used in the present thesis, given that the respective 
primers bind within intron 6/7 of SLC2A3 (nearby Chr12:8081061), i.e. a DNA 
sequence that should only appear once in the B5/B6 duplication allele.   
 
On the other hand, Reekie thoroughly described a deletion allele at 12p13.31 that 
she suggested to be associated with a lower risk of developing the autoimmune 
disorder rheumatoid arthritis (based on an association study of a Swedish and British 
population sample). Such a deletion corresponds to a SLC2A3 copy number of 1, 
which was also found in a number of samples of the Department of Psychiatry in 
Würzburg via TaqMan- and SNP array-based CNV analysis. Until present, this 
deletion cohort has not been included in studies, owing to its comparably low sample 
size and absence of a consistent clinical phenotype. In contrast to mice 
demonstrating autism-like behavioural features when heterozygously deficient for 
Slc2a3 (Zhao et al., 2010), a clear-cut clinical picture of psychiatric disorders has not 
yet been observed in terms of human SLC2A3 deletion carriers. Future work will 
possibly shed light on whether the potential physiological consequences of 
diminished SLC2A3 copy number may constitute a quasi-reversed effect of those 
accompanying an increased copy number, or whether a heterozygous deficiency of 
SLC2A3 can be compensated comparatively easily.  
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4.1.2 Quantitative reverse transcription (qRT) PCR 
As expected, duplication of the SLC2A3 gene was accompanied by substantially 
elevated SLC2A3 mRNA levels both in lymphoblastoid cell cultures (LCLs) and 
native peripheral blood mononuclear cells (PBMCs). Considering that a copy number 
gain from 2 to 3 should theoretically involve 50% higher amounts of corresponding 
gene product, measured increases were even more pronounced than anticipated. 
The qRT-PCR results revealed highly significant differences between carriers of 2 
and 3 SLC2A3 gene copies, namely an upregulation of SLC2A3 gene expression in 
the latter group by more than 200% in terms of PBMCs, and more than 70% in terms 
of immortalised cells (LCLs). At least the latter result complies with the findings 
reported by Yang and colleagues in 2009, who found significantly elevated SLC2A3 
mRNA levels (approximately 75%) in SLC2A3 duplication carriers when analysing 48 
fibroblast samples via qRT-PCR (Yang et al., 2009). 
 
4.1.3 Western blotting 
Despite striking genotype effects at mRNA level, corresponding protein amounts 
were found to be unremarkable. Semi-quantitative analysis of whole-cell GLUT3 
protein did not result in any significant differences between carriers of 2 and carriers 
of 3 SLC2A3 gene copies, neither in LCLs nor in PBMCs.  
When considering the Western blotting data, comparatively high standard errors of 
the mean (SEM) are notable in both genotype groups, amounting to approximately 
20% of the respective mean values and hence around twice as much as for the qRT-
PCR data. Accordingly, this indicates a higher method- and/or biology-based 
variance for GLUT3 protein, hindering the identification of potential genotype effects. 
 
However, on the other hand, inconsistencies between mRNA and protein levels of 
glucose transporters have been previously reported in comparable studies. In a gene 
expression analysis of PBMCs, Estrada and colleagues did not detect any correlation 
between SLC2A3 mRNA and GLUT3 protein amounts (Estrada et al., 1994), neither 
did the authors of a study focusing on SLC2A4 expression in muscle cells (Bourey et 
al., 1990).  
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One possible explanation for this peculiar finding is that pre-translational 
mechanisms may delimit the quantity of glucose transporter protein being produced 
in these peripheral cells under basal conditions, thus masking increased SLC2A3 
mRNA levels detected in SLC2A3 duplication carriers. Such regulatory mechanisms 
of GLUT3 have been suggested for example in a study focusing on the expression of 
glucose transporters in early rat brain (Nehlig et al., 2006), with the authors 
discovering that seizure-induced upregulation of Slc2a1 and Slc2a3 mRNA was not 
accompanied by an increase of respective protein levels, implying a storage of 
untranslated mRNA within the cytoplasm.  
 
Moreover, the inconsistencies may also be attributed to post-translational 
mechanisms. Many cells are able to adapt to situations of altered energy demand by 
changing the ratio of active to inactive glucose transporter molecules. This is known 
to happen via trafficking of different GLUT isoforms from intracellular vesicular pools 
to the cellular surface (Wilson et al., 1995; Malide et al., 1998). Despite unremarkable 
whole-cell GLUT3 protein levels, it is thus conceivable that the subcellular distribution 
of GLUT3 protein may still differ between carriers of 2 and 3 SLC2A3 gene copies. 
Additional methods such as fluorescence microscopy or cell fractionation, will 
probably help to investigate the proportion of GLUT3 protein in the plasma 
membrane. Another post-translational regulatory principle for glucose transporters 
was introduced by Khayat and colleagues in 1998. The authors referred to the 
regulatory effect of the chemical compound 2,4-dinitrophenol (DNP), which is well-
known as an uncoupler of mitochondrial oxidative phosphorylation, giving rise to a 
rapid decline of cellular ATP. When chronically exposed to DNP, rat muscle cells 
were found to exhibit a variety of adaptive responses, leading to elevated cellular 
uptake of glucose, among others. Interestingly, this is not only achieved by de novo 
biosynthesis of GLUT1 and GLUT3 but also by prolonging the half-lives of both 
proteins. In this respect, the turnover rates of GLUT3 particularly emerged as being 
regulable over a wide range (Khayat et al., 1998). Therefore, metabolic labeling of 
cells with [35S]methionine, as was performed in that study, may also constitute a 
useful tool for comparing the biosynthesis and degradation of GLUT3 in vivo between 
carriers of different SLC2A3 copy number.  
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4.1.4 Cellular glucose uptake assay 
An additional gene copy of SLC2A3 did not emerge to be accompanied by a 
significantly altered cellular glucose uptake in our immortalised peripheral cell model 
(LCLs). Despite being consistent with the aforementioned Western blotting results for 
LCLs that indicated similar whole cell GLUT3 protein amounts in SLC2A3 duplication 
carriers and controls, this data does not correspond with our initial hypothesis, 
predicting a positive correlation between SLC2A3 copy number and glucose uptake.  
Supposing that all cell culture results are valid, a very likely explanation for this 
unexpected outcome is that regulatory mechanisms in these peripheral cells (see 
chapter 4.1.3) restrict the total GLUT3 amounts and hence the glucose transport, 
despite enhanced SLC2A3 mRNA levels. In this regard, it is certainly interesting to 
question whether such regulatory mechanisms constitute an individual feature of 
peripheral (blood) cells or if they also occur in the brain. Investigating central glucose 
metabolism via Positron emission tomography (PET) or using a neuronal cell model 
with SLC2A3 overexpression may help to approach this problem.  
 
Furthermore, the question arises of whether an additional SLC2A3 gene copy could 
be redundant in situations of sufficient energy supply (as is possibly the case in our 
peripheral cell model under basal conditions) yet might constitute a metabolic 
advantage when cellular energy sources run short. Accordingly, it may be very useful 
to investigate the effects of glucose deprivation or treatment with substances that 
target cellular respiration (e.g. the aforementioned DNP) on our cell cultures.   
 
Similar to the Western blotting data, SEM values of glucose uptake were rather high 
(~15% of the respective mean values in the duplication group and ~20% in controls), 
indicating a pronounced statistical variance and consequently constraining the 
evaluation of the glucose uptake. SEM values were initially even higher, but could be 
substantially improved by modifications of the experimental protocol; for example, in 
terms of pre-incubation of cells in 24-well plates, or the centrifugal speed. To 
disentangle whether this high variance is rather due to physiological or technical 
factors, future uptake experiments should involve alternative methods such as flow 
cytometry or other cell models such as fibroblasts. In principle, uptake experiments 
can also be performed with native cells as reported for instance by Piątkiewicz and 
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colleagues, working with PBMCs (Piatkiewicz et al., 2007). Using native cells reduces 
potential artefacts caused by the immortalisation and cultivation of cells, yet involves 
other problems, such as the delimited viability and availability of cells. Moreover, in 
contrast to LCLs, which are considered a homogenous population of EBV-
transformed B lymphocytes (Sie et al., 2009), PBMCs constitute a heterogeneous 
mixture of various mononuclear cell types (~60% T lymphocytes, ~15% monocytes/ 
macrophages, ~15% natural killer cells and ~10% B lymphocytes; Rowland-Jones 
and McMichael, 1999), thus hindering clear-cut interpretations.  
 
4.1.5 Functional EEG measurements 
For this experiment, participants underwent a Continuous Performance Test (CPT) 
and n-back test while an ongoing electroencephalogram (EEG) was recorded in 
parallel. Both CPT and n-back are neuropsychological tests that have been proved 
reliable and valuable in assessing a variety of cognitive traits, particularly cognitive 
response control (in terms of the CPT) and working memory (in terms of the n-back 
test), namely two traits discussed as endophenotypes for ADHD (for a review, see 
Fallgatter et al., 2005; Kasper et al., 2012) 
 
CPT 
Concerning our CPT-linked measurements, significantly diminished NoGo-
Anteriorisation (NGA) values emerged in ADHD patients with 3 SLC2A3 gene copies 
compared to those in the ADHD group carrying two copies. Given that NGA is 
regarded as an endophenotypic marker of prefrontal brain activity during processes 
of cognitive response control (Fallgatter et al., 2012), this result is indicative of 
altered prefrontal functioning.  
 
Surprisingly, the effect was due to the centroid of the Go-condition being located 
considerably more anterior in duplication carriers with ADHD while NoGo-related 
centroids did not show a group difference. However, this quite exceptional pattern 
has been previously observed, namely within a study focusing on ADHD risk alleles 
of the TPH2 gene (Baehne et al., 2009). The authors reported that participants 
carrying the rs11178997 T/T-allele had a significantly smaller NGA than those with 
T/A-allele, which could be attributed to more anterior Go-centroids in the first group. 
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Although this result did not allow clear-cut assumptions about altered EEG 
topography during response inhibition (as opposed to response execution), it was still 
suggestive of an exceptional (prefrontal) brain functioning in rs11178997 T/T-allele 
carriers during the whole task. Accordingly, the aforementioned aberrant 
topographical EEG pattern of SLC2A3 duplication carriers within the ADHD group 
can be interpreted as an indicator of altered brain activity during a cognitive response 
control task, albeit not as clear-cut proof of impaired response inhibition itself.  
 
On the other hand, our CPT-linked EEG measurements for the SLC2A3 CNV did not 
confirm a general effect of ADHD status: irrespective of SLC2A3 copy number, the 
ADHD group did not show lower NGA values than healthy controls, as was expected 
based upon previous reports (Fallgatter et al., 2005). However, taking the rather 
small sample size into account, this observation may simply be due to a lack of 
statistical power and the stratification of ADHD samples on the basis of differing 
genotype. Indeed, the tendency towards diminished NGA amounts in SLC2A3 
duplication carriers of the ADHD group compared to healthy SLC2A3 duplication 
carriers speaks in favour of this notion. 
 
Beyond that, we found an interaction between genotype and ADHD diagnosis in 
another CPT analysis, focusing on the SNP rs12842 within the SLC2A3 gene. It 
emerged that ADHD patients with a C-allele at this genomic position exhibited 
significantly reduced NGA values when compared to healthy controls with the same 
allele. Additionally, within the ADHD patient group, NGA values emerged to be 
marginally higher in T-allele than in C-allele carriers, albeit without reaching the level 
of significance. According to the NCBI reference assembly hg19, rs12842 is a 
biallelic SNP, with ‘C’ being the ancestral and ‘T’ the minor allele (global minor allele 
frequency: 0.093). The polymorphism is located within the 3' untranslated region 
(3’UTR) of SLC2A3 mRNA (see Figure 5), implying that the substitution of cytosine 
by thymine does not affect the amino acid sequence of the translated protein. 
However, it is conceivable that this SNP within the 3’UTR may exert influence on the 
secondary structure and stability of SLC2A3 mRNA, thereby altering its translational 
efficiency (for a review, see Mazumder et al., 2003). While the rs12842 T-allele was 
found to be significantly over-transmitted to offspring affected by ADHD (Merker et 
al., manuscript in preparation), at present there is no clinical relevance known for the 
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C-allele. The first finding, i.e. significantly lower NGA values in ADHD patients than in 
healthy controls (yet only in terms of C-allele carriers), is consistent with earlier 
reports suggesting reduced NGA as a useful marker for ADHD-related 
endophenotypes (Fallgatter et al., 2005). Although a clear-cut genotype effect could 
not be determined for rs12842, the significant interaction effect between the variables 
‘genotype’ and ‘diagnosis’ still speaks in favour of an implication of this SNP in 
ADHD. Moreover, the trend towards higher NGA values in T-allele carriers was very 
close to the level of significance (p=0.058) and thus should not be completely 
omitted. Based on the present data, it appears that the rs12842 T-allele differentially 
influences EEG topography in response control tasks, which is apparently 
accompanied by an amelioration of reduced NGA in ADHD patients. According to this 
view, the T-allele possibly seems to have a rather beneficial influence on altered 
prefrontal brain functioning in ADHD patients during processes of cognitive response 
control. Naturally, replicating the experiment with other cohorts and larger sample 
sizes is essential to draw a more reliable conclusion. 
 
n-back test 
Subgroups of adult ADHD patients and healthy participants carrying either two or 
three SLC2A3 gene copies were investigated with ERP recordings during an n-back 
task. Essentially, EEG data revealed drastically diminished P300 amplitudes in 
ADHD patients carrying three SLC2A3 copies compared to subjects with the same 
diagnosis yet without the duplication. Given that the P300 component is commonly 
regarded as a measure of attentional and working memory processes (Polich, 2007), 
the results indicate a considerable impact of SLC2A3 copy number on these mental 
processes.  
 
Working memory is well-known as an attention-requiring limited capacity to hold and 
manipulate information in the mind for several seconds, and is considered to play an 
important role in reasoning, comprehension, planning and learning (Baddeley, 1992). 
In accordance with this definition, which underlines the importance of attention, 
significant working memory deficits have been described for ADHD patients both 
during child- (Kasper et al., 2012) and adulthood (Hervey et al., 2004).  
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When analysing working memory or other processes based upon tasks that involve 
an active decision, a pronounced positive voltage deflection can be measured at the 
participant’s scalp in an interval around 300-500ms after stimulus onset. A 
subelement of this late positive ERP component, P300, is considered sensitive to the 
attentional and working memory demands of the task: in situations when attention is 
exclusively focused on one issue, P300 amplitudes emerged larger than usual, 
whereas the reverse is true (i.e. decreased amplitudes) whenever attention was 
compromised by other mental activities, or when information storage in the working 
memory occurred competitively (Gevins et al., 1996; McEvoy et al., 1998). 
 
The influence of SLC2A3 copy number on P300 amplitudes during the n-back was 
particularly prominent during target trials in our experiments, i.e. when participants 
were actually supposed to react, as well as under 1-back conditions, i.e. when 
participants required memory for stimuli occurring exactly 1 trial previously. The first 
result suggests that the late positive ERP to non-matching stimuli was higher than 
that of matching ones as also reported within other studies, and ascribed to the 
higher amount of resources required for updating the working memory in terms of 
non-matching stimuli (McEvoy et al., 1998). The second result underscores the 
relevance of nominal task difficulty and required memory load, although both were 
comparatively low in this case (1-back condition). A possible interpretation of this 
discovery is that reduced P300 amplitudes of SLC2A3 duplication carriers with ADHD 
may ameliorate when the complexity of the challenge, and thus the cognitive effort, 
drive the participant’s attention to the task. 
 
Interestingly and similar to our findings in the aforementioned CPT, the genotype 
effect was restricted to the ADHD group, i.e. n-back test-related P300 amplitudes did 
not significantly differ between healthy carriers of two or three SLC2A3 copies. It 
remains to be elucidated if these results are owing to a lack of statistical power, or 
whether they are indicative of an interaction effect between SLC2A3 genotype and 
ADHD. Unlike respective CPT results, the lack of a significant association of the 
duplication status with working memory in healthy controls (p>0.25) rather speaks in 
favour of the assumed interaction effect. 
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While rs12842 genotype status had no significant influence on n-back test-related 
P300 amplitudes, the ERP component ‘N200’ was overall affected by trend (p<0.1). 
N200 is known as a negative-directed EEG wave that is evoked ~200 to 350ms after 
the onset of a specific visual or auditory stimulus, and is suggested to be associated 
with conflict processing and executive cognitive control functions (Folstein and van 
Petten, 2008). Notably, the latency of N200 was reported to be changeable as a 
function of discrimination difficulty, which implies increased N200 latencies in 
situations when decision-making is rather tough (Towey et al., 1980). 
 
In our case, a closer observation of the genotype effect revealed that rs12842 C-
allele carriers displayed significantly increased N200 latencies in non-target trials 
compared to target trials, across diagnostic groups and n-back test conditions. 
Interestingly, such an effect did not occur within the group of T-allele carriers 
exhibiting quite steady N200 latencies, independent of trial type, n-back test condition 
or ADHD diagnosis. The aforementioned observation of Towey and colleagues, 
suggesting a positive correlation between N200 latencies and discrimination difficulty, 
and thus higher latencies in 2-back than in 1-back conditions, could not be generally 
confirmed; rather, the ADHD subgroup of C-allele carriers only showed this effect in 
terms of non-target conditions, whereas all healthy subgroups appeared relatively 
modulation-resistant.  
 
Overall, our findings indicate a rather negative influence of the rs12842 C-allele 
compared to the T-allele, given that increased (i.e. delayed) N200 latencies following 
non-target stimuli have been discussed as markers for slowed automatic cognitive 
processing and weakened cognitive inhibition (Wang et al., 1999; Williams et al., 
2000). In this respect, our n-back data is consistent with the aforementioned CPT 
results, pointing towards higher (i.e. ameliorated) NGA values in ADHD patients with 
T-allele than those with C-allele. Moreover, similar to all aforementioned EEG results, 
genotype effects on N200 latencies were considerably more pronounced in the 
ADHD than the healthy control group, strongly supporting the assumed interaction 
effect between SLC2A3 gene variants and this neurodevelopmental disorder. 
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4.2 Lphn3 
4.2.1 Confirmation of homologous recombination in murine ES cells 
Following electroporation and antibiotic selection of ES cells, a multitude of 
techniques were used to check whether the Lphn3 targeting vector was actually 
taken up by the cells as well as if the Lphn3.flx/frt construct within the vector was 
entirely and correctly integrated into the ES cell genome by replacing the respective 
wildtype allele. 
 
According to the International Knockout Mouse Consortium (IKMC; 
www.knockoutmouse.org), several quality checks for ES cells are generally 
recommended before commencing with the generation of chimeric mice, not least 
PCR-based assays. Such experiments are intended to not only confirm the presence 
of highly important vector-specific DNA sequences (via short-range PCR) but also the 
proper, i.e. site-directed, integration of the vector construct into the respective 
genomic locus (via long-range PCR).  
 
In terms of our ES cell clones, three different short-range PCR and one long-range-
PCR assays were designed. Starting with the short-range PCRs, we were able to sort 
out all clones that repeatedly did not give rise to amplicons of the correct size in all 
three PCRs, indicating the absence of one or multiple essential vector construct-
specific DNA sequences (5’ FRT, 3’ FRT and 3’ loxP site). Using a positive (Lphn3 
targeting vector DNA) and negative control sample (wildtype ES cell clone DNA) in 
parallel to the transfected ES cell samples, the short-range PCR experiments proved 
reliable. 
To verify whether the vector construct was not only present within the ES cells but 
also correctly integrated into their genome, a long-range PCR spanning the whole 5’ 
homology arm was performed. Owing to the nature of this integrative PCR (involving 
a forward primer that does not bind within the targeting vector), we were unable to 
apply a positive control sample, thus hindering the establishment of this assay. 
Nevertheless, the long-range PCR proved useful in selecting a fistful of ES cell 
clones that unambiguously exhibited the expected amplicon of 4.8kb.  
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The aforementioned web page of the IKMC also mentions a supplementary method 
that helps reliably verifying site-directed homologous recombination in ES cells, 
namely Southern blotting. According to the IKMC, around 18% of ES cell clones that 
emerge positive in two or more different PCR-based quality checks still do not pass a 
subsequent Southern blotting assay, which is probably due to irregular recombination 
events or mixed clones. 
Therefore, we decided to confirm the correct integration of the Lphn3.flx/frt construct 
at the 3’ homology arm via a Southern blotting analysis. By testing those ES cells 
that passed all preceding PCR assays, we found that 8 of 10 clones clearly gave rise 
to the anticipated 7.9kb fragment, representing the correctly recombined allele, 
whereas the remaining two clones only exhibited the 9.5kb wildtype fragment. 
Accordingly, our Southern blotting-related rejection rate resembled that determined 
by the IKMC. However, owing to the slightly distorted band front-line and particularly 
the high overall background (which unfortunately could not be improved without 
losing the target band signals), the assessment of our Southern blotting membrane 
was rather difficult. Consequently, some samples had to be repeated and were 
rejected in case of ongoing doubt. Though unlikely, it may thus be the case that the 2 
discarded ES cell clones were false-negatives – a possibility that remained 
acceptable given the number of clearly positive samples.  
 
4.2.2 Additional quality checks for recombined ES cells 
Despite not being included in the IKMC list of quality checks, we further decided to 
check the correctness of some crucial sequences (FRT and loxP sites) within the 
Lphn3.flx/frt allele via DNA sequencing. Importantly, the results showed that all 
amplicons fully complied with the predicted sequences, indicating functional integrity 
of respective sites. Admittedly, we did not check the correctness of all three loxP 
sites within the construct: the single loxP site in between the lacZ cassette and the 
neomycin resistance cassette (see Figure 7), enabling separately removing the latter, 
was considered rather negligible and thus not included in the sequencing assay.  
 
As recommended by the IKMC, further quality checks for ES cells comprised a 
Mycoplasma test and chromosome counting (karyotyping). Fortunately, the PCR-
based Mycoplasma test revealed only the negative control amplicon when using DNA 
                                                                                                                      Discussion 
___________________________________________________________________________________________________________________________________________________________________                                                 
66 
extracts of ES cell clones, suggesting that they were all free of Mycoplasma bacteria, 
which are known to constitute a detrimental factor for several cell parameters and 
postnatal development of the resulting chimeric mice (Markoullis et al., 2009).  
Furthermore, karyotyping revealed that our ES cell clones were euploid and exhibited 
macrostructurally normal chromosomes in all but one case. Given that aneuploidy 
and other chromosomal anomalies in ES cells were shown to interfere with their 
capability to contribute to the germline in mice (Liu et al., 1997), this finding was very 
vital for our subsequent experiments.  
 
An elementary yet very essential quality check was naturally also the surveillance of 
ES cell morphology. Despite our ES cells being constantly grown on SNL feeder cells 
and in fresh medium that contained Leukemia Inhibitory Factor (LIF), i.e. in an 
environment that suppressed differentiation processes (Williams et al., 1988), they 
were nonetheless inspected frequently and by different persons. Fortunately, the 
aforementioned ES cell clones appeared morphologically normal and undifferentiated 
throughout the whole cultivation phase. 
 
With an overall quantity of 7 ES cell clones being positive for all quality checks, we 
eventually had an even higher number than recommended by the European Mouse 
Mutant Cell Repository (EuMMCR), suggesting the use of at least 3 ES cell clones 
per gene to ensure germline transmission in mice.  
 
4.2.3 Generation of chimeric mice 
A comparably advanced method was applied for the generation of mice embryos, 
relying on (laser-assisted) injection of ES cells into murine eight cell-stage embryos 
(morulae). In contrast to classical blastula injection techniques, this procedure allows 
the efficient production of mice whose body cells almost entirely derive from injected 
cells, considerably enhancing germline transmission rates without interfering with 
their viability or health (Poueymirou et al., 2007). 
 
Indeed, we were able to generate highly chimeric, phenotypically unremarkable and 
(with some exceptions) fertile mice by using 4 of the aforementioned 7 ES cell 
clones. Unfortunately, evidence has yet to be found indicating that the Lphn3.flx/frt 
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allele was inherited to the offspring of the chimeras. All tested animals only gave rise 
to the Lphn3 wildtype amplicon in an allele-specific PCR assay, which was double-
checked and appeared reliable in terms of the negative and positive controls. 
Moreover, all offspring produced so far (>100 animals) were of black coat colour, 
strongly arguing against germline transmission of injected ES cells (which in our case 
derive from mice heterozygously carrying the dominant agouti coat colour gene). 
However, the project is still in progress. Indeed, as the 4 ES clones were not injected 
simultaneously but rather with a large time-delay, our chimeric mice are of different 
ages. Therefore, more than 50% of the chimeras still are too young to be mated, and 
their expected offspring has yet to be genotyped. Given that our ES cell clones were 
thoroughly tested before morula injection and derive from the cell line ‘JM8A3’, which 
is reported to have a germline transmission rate around 82% (Pettitt et al., 2009), 
there currently is no reason to seriously doubt the quality of our cell clones and 
hence the success of the entire project.   
 
 
 Conclusion and outlook 
___________________________________________________________________________________________________________________________________________________________________                                                 
68 
5 Conclusion and outlook 
5.1 SLC2A3 
Overall, our results indicate that SLC2A3 polymorphisms associated with ADHD are 
accompanied by transcriptional and functional changes in humans. In peripheral 
blood cell models, SLC2A3 duplication carriers displayed dramatically increased 
SLC2A3 mRNA levels, whereas corresponding GLUT3 protein amounts and overall 
glucose uptake appeared unaltered under basal conditions. ADHD patients with 
SLC2A3 duplication exhibited significantly diminished NGA values when observing 
ERP recordings during a test of cognitive response control, possibly involving altered 
prefrontal brain activity. By contrast, this effect appeared reversed in ADHD patients 
carrying the T-allele of the ADHD-associated SNP rs12842 when compared to 
respective C-allele carriers. Moreover, during a neuropsychological test of working 
memory, EEG measurements of SLC2A3 duplication carriers within the ADHD group 
revealed drastically reduced P300 amplitudes, suggestive of altered attention and 
working memory processes, whereas no such influence was observed for the SNP 
rs12842. However, T-allele carriers in both diagnostic groups showed lower N200 
latencies in response to non-target stimuli than participants with C-allele, possibly 
reflecting faster cognitive processing in the former. Overall, our EEG findings suggest 
that the SLC2A3 CNV (duplication) and SNP (rs12842 T-allele) exert dissimilar or 
even opposed effects on various EEG parameters, indicative of opposed molecular 
mechanisms; moreover these genotype effects generally were much more 
pronounced in the ADHD group, implying a considerable interaction.  
 
A large debate has recently emerged concerning the complex genetic topography of 
ADHD, with some studies showing the impact of common variants such as SNPs and 
others emphasising the effect of rare variants such as CNVs. In this regard, our 
SLC2A3 study somewhat constitutes an amalgamation that combines these 
competing models and underlines the broad continuum between both extremes, i.e. 
common variants with small effect size and arising from very distant ancestors on the 
one hand and extremely rare de novo variants with very large effect size on the other 
(Lupski et al., 2011). Given the comparably little research conducted in terms of 
ADHD-associated CNVs to date, our findings may contribute to shed some light on 
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the murk of ADHD genetics, including the question of ‘missing heritability’, namely 
the considerable percentage of heritability for many complex traits and diseases that 
is presently unaccounted for (Manolio et al., 2009).  
 
Future research of SLC2A3 polymorphisms will possibly comprise a variety of 
techniques and models. For human carriers of SLC2A3 variants, additional functional 
methods could be used such as fMRI imaging during food-related tasks or PET 
imaging of central glucose metabolism. As indicated in the discussion (chapter 4.1.1), 
this may also include participants showing a deletion of SLC2A3, which has not yet 
been associated with a particular phenotype in human. To obtain a suitable animal 
model for the SLC2A3 CNV, it is conceivable to develop and characterise a mouse 
line overexpressing the orthologous gene Slc2a3. Additionally, other cellular models 
might be established, for example SLC2A3-overexpressing primary neurons or 
neuronal cell cultures deriving from reprogrammed fibroblasts (Vierbuchen et al., 
2010). Overall, these and other models may particularly help to elucidate the 
molecular networks that somewhat compose the ‘black box’ in between genes and 
behaviour, i.e. in our case the ‘black box’ between polymorphisms of a certain 
glucose transporter gene and the complex traits representing the neurobehavioural 
disorder ADHD.  
 
5.2 Lphn3 
Given that this project involves the principal goal of developing a Lphn3 mouse 
model with conditional knockout potential, intermediate results are available at this 
point. Indeed, we were able to successfully transfect murine ES cells with a Lphn3 
targeting vector and confirm correct homologous recombination between the vector 
and the genomic Lphn3 locus via several PCR- and Southern blotting-based assays. 
Moreover, we performed various quality checks for these cells, such as DNA 
sequencing, Mycoplasma testing and karyotyping. Overall, our tests led to more than 
half a dozen positive ES cell clones, some of which were used for subsequent 
microinjection of murine morulae. Numerous highly chimeric and phenotypically 
unremarkable mice were generated by this means and crossed with wildtype 
animals, albeit without yet giving rise to germline transmission of the Lphn3.flx/frt 
allele. Fortunately, there is a distinct chance of achieving the goal in the near future, 
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as the majority of our chimeras are currently too young to produce offspring and thus 
are yet to be tested for germline transmission. 
 
Given the large number of recent publications underscoring the implication of the 
gene LPHN3 in several physiological processes and psychiatric disorders such as 
ADHD, the establishment of an appropriate mammalian model of latrophilin-3 
deficiency certainly constitutes an important prerequisite for future research of this 
gene. Generating a mouse line that exhibits the Lphn3.flx/frt allele involves several 
considerable advantages. For instance, owing to the lacZ trapping cassette within the 
gene construct, it is possible to simultaneously disrupt and report Lphn3 gene 
function in vivo. Consequently, mice homozygously carrying this allele are expected 
to resemble constitutive Lphn3 knockout animals (knockout-first principle), enabling 
an early phenotypical characterisation. Moreover, the lacZ reporter gene provides the 
opportunity to reliably analyse the expression pattern of Lphn3 in mice via beta-
galactosidase staining of (brain) tissue (Kaelin et al., 2004). Importantly, the 
Lphn3.flx/frt allele can also be modified in vivo when crossing respective mice with 
transgenic animals expressing Flp recombinase. By this means, it is possible to 
remove both the lacZ and neo cassette, resulting in a ‘clean’ floxed allele, which is a 
prerequisite for the conditional knockout of murine Lphn3 in a time- or tissue-specific 
manner (e.g. only in dopaminergic cells). The subsequent phenotypical analysis of 
such a mouse line may involve a multitude of aspects and methods, such as 
morphology, immunohistochemistry and neuroimaging, and also electrophysiology, 
pharmacology and not least behaviour, thus likely providing a comprehensive view. 
As mentioned in chapter 1.1.7 describing the evaluation of animal models, this 
multifaceted analysis will also serve to check whether or not conditional Lphn3 
knockout mice meet all required validity criteria and thus can be considered an 
appropriate mammalian model of ADHD. 
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